

**Neurons burdened by DNA double strand breaks incite microglia activation  
through antiviral-like signaling in neurodegeneration.**

Gwyneth Welch<sup>1,2</sup>, Carles Boix<sup>3</sup>, Eloi Schmauch<sup>3,4,5</sup>, Jose Davila-Velderrain<sup>3</sup>, Matheus B. Victor<sup>1,2</sup>, Vishnu Dileep<sup>1,2</sup>, Lorenzo Bozzelli<sup>1,2</sup>, Qiao Su<sup>6</sup>, Jemmie Cheng<sup>1,2</sup>, Audrey Lee<sup>1,2</sup>, Noelle Leary<sup>1,2</sup>, Andreas Pfenning<sup>6</sup>, Manolis Kellis<sup>3,4</sup>, and Li-Huei Tsai<sup>1,2,4,\*</sup>

1. Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA.
2. Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA.
3. Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA, USA.
4. Broad Institute of Harvard and MIT, Cambridge, MA, USA.
5. A. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
6. Carnegie Mellon University Departments of Computational Biology and Biology and Neuroscience Institute, Pittsburgh, PA, USA.

\*To whom correspondence should be addressed: [lhtsai@mit.edu](mailto:lhtsai@mit.edu)

## 2 **Summary**

3 It is unclear how age-associated DNA double strand break (DSB) accumulation in neurons  
4 influences the progression of cellular senescence and neurodegenerative disease. Here, we  
5 leverage mouse models of neurodegeneration, single-nucleus, bulk, and spatial transcriptomics  
6 from Alzheimer's disease patients, mouse models, and primary neuron cultures to dissect the  
7 immune signaling pathways initiated by DSB-bearing neurons that trigger neuroinflammation.

## 8 **Abstract**

9 DNA double strand breaks (DSBs) are linked to aging, neurodegeneration, and senescence<sup>1,2</sup>.  
10 However, the role played by neurons burdened with DSBs in disease-associated  
11 neuroinflammation is not well understood. Here, we isolate neurons harboring DSBs from the CK-  
12 p25 mouse model of neurodegeneration through fluorescence-activated nuclei sorting (FANS),  
13 and characterize their transcriptomes using single-nucleus, bulk, and spatial sequencing  
14 techniques. We find that neurons harboring DSBs enter a late-stage DNA damage response marked  
15 by the activation of senescent and antiviral-like immune pathways. We identify the NFkB  
16 transcription factor as a master regulator of immune gene expression in DSB-bearing neurons, and  
17 find that the expression of cytokines like *Cxcl10* and *Ccl2* develop in DSB-bearing neurons before  
18 glial cell types. Alzheimer's Disease pathology is significantly associated with immune activation  
19 in excitatory neurons, and direct purification of DSB-bearing neurons from Alzheimer's Disease  
20 brain tissue further validates immune gene upregulation. Spatial transcriptomics reveal that regions  
21 of brain tissue dense with DSB-bearing neurons also harbor signatures of inflammatory microglia,  
22 which is ameliorated by NFkB knock down in neurons. Inhibition of NFkB or depletion of *Ccl2*  
23 and *Cxcl10* in DSB-bearing neurons also reduces microglial activation in organotypic brain slice

24 culture. In conclusion, we find that in the context of age-associated neurodegenerative disease,  
25 DSBs activate immune pathways in neurons, which in turn adopt a senescence associated secretory  
26 phenotype to elicit microglia activation. These findings highlight a novel role for neurons in the  
27 mechanism of age-associated neuroinflammation.

## 28 **Introduction**

29 Loss of genomic integrity is linked to aging and neurodegeneration<sup>1,2</sup>. DNA damage repair  
30 pathways are transcriptionally prominent in the aging brain, and many age-associated  
31 neurodegenerative diseases exhibit both accumulation of DNA lesions and reduced DNA repair  
32 efficiency<sup>3-7</sup>. The most toxic of these lesions, the DNA double strand break (DSB), can drive many  
33 phenotypes of aging including senescence, mutation, and cell death. Postmitotic neurons are  
34 particularly susceptible to these threats due to their long lifespan, high metabolic activity, and  
35 limited DSB repair capacity. While DSB accumulation in neurons is a well-documented feature of  
36 aging and neurodegeneration, the transcriptional profile adopted by such population of neurons  
37 remains largely unknown.

38 The accumulation of DSBs is an early feature of Alzheimer's Disease (AD), suggesting that they  
39 may act as an initiating lesion of toxicity<sup>8</sup>. Multiple mouse models of neurodegeneration  
40 phenocopy increased DSBs at early pathological stages, including the P301S tauopathy model, the  
41 inducible CK-p25 model, and the 3xTg and hAPP-J20 amyloid pathology models<sup>9-13</sup>. In addition,  
42 induction of DSBs are sufficient to induce organismal aging and neurodegenerative phenotypes in  
43 mice<sup>14</sup>. Recent studies characterizing single and double strand breaks in postmitotic neurons reveal  
44 that break location may underlie the toxicity of DNA damage in aging and neurodegenerative

45 disease<sup>15,16</sup>. However, regardless of location, the downstream biological effects of DSB  
46 accumulation in neurons are unclear.

47 Here, we aimed to characterize the biological consequences of DSB accumulation in neurons. We  
48 also investigated how this impacts mechanisms of neuroinflammation in age-associated  
49 neurodegenerative disease. We utilized fluorescence-activated nuclei sorting (FANS) followed by  
50 bulk and single-nucleus RNA-sequencing to transcriptionally characterize neurons burdened with  
51 DSBs in the CK-p25 mouse model of neurodegeneration. We found that DSB-bearing neurons  
52 activate innate immune signaling pathways reminiscent of those expressed by senescent cells and  
53 virally infected neurons<sup>17-24</sup>, and that this is accompanied by degradation of neuronal identity. The  
54 gene expression patterns of DSB-burdened neurons were enriched in excitatory neurons from AD  
55 postmortem human brain. Purified DSB-bearing neurons from the human brain also exhibited an  
56 enrichment of immune gene signatures. Spatial transcriptomics of the CK-p25 forebrain revealed  
57 signatures of microglial inflammation were closely associated with DSB-bearing neurons.  
58 Correspondingly, suppression of the NFkB transcription factor in neurons impacted measures of  
59 neuroinflammation in microglia at early stages of disease. Together, these data establish a novel  
60 signaling relationship between neurons burdened with DSBs and microglia in age-associated  
61 neurodegenerative disease.

## 62 **Results**

### 63 **Identification of DSB-bearing neurons at early stages of disease in a mouse model of** 64 **neurodegeneration.**

65 We utilized the CK-p25 mouse model of inducible neurodegeneration to understand how DSB-  
66 bearing neurons contribute to disease development. In these mice, the *CamkII* promoter drives the

67 expression of the neurotoxic protein fragment p25 through a doxycycline-off system<sup>25</sup>. P25 is the  
68 calpain-cleaved product of p35, an activator of cyclin dependent kinase 5 (Cdk5). Previously, we  
69 determined that the first pathologies observed in these mice are increased DSBs in neurons<sup>9</sup> and  
70 activation of microglia<sup>26</sup>. These pathologies occur 1-2 weeks after the onset of p25 expression  
71 when mice are taken off doxycycline (dox). Intracellular amyloid-beta accumulation occurs as  
72 early as 2-3 weeks after induction<sup>27</sup>. Neuronal loss, learning deficits, and tau hyperphosphorylation  
73 are also observed in the following 4-12 weeks<sup>25,27,28</sup>. These pathological events are inducible and  
74 occur in a highly concerted and predictable manner<sup>29</sup>.

75 The phosphorylation of the histone variant H2A.X ( $\gamma$ H2AX) by ATM kinase occurs rapidly after  
76 DSB detection. This post-translational histone modification is essential for efficient DSB  
77 recognition and repair, and is a robust DSB biomarker<sup>30</sup>. Using flow cytometry, we identified a  
78 distinct population of  $\gamma$ H2AX-positive nuclei at the two-week time point in the CK-p25 cortex,  
79 but not in the CK control cortex (Figure 1a). CK mice express the *CamkII*-driven tetracycline  
80 transactivator (tTA), but not p25. A timeline analysis was also performed to determine when  
81  $\gamma$ H2AX-positive nuclei begin to accumulate in the CK-p25 cortex.  $\gamma$ H2AX-positive nuclei were  
82 detectable as early as one week after induction ( $1.038 \pm 0.2627$  % population), peaked at two  
83 weeks ( $4.614 \pm 0.9416$  % population), and gradually decreased thereafter (Figure 1b). The  
84 significant reduction in  $\gamma$ H2AX-positive nuclei at six weeks corresponds with previous  
85 observations of neuronal loss in this model, suggesting that  $\gamma$ H2AX-positive cells degenerate by  
86 six weeks<sup>25,28</sup>. We were able to observe similar  $\gamma$ H2AX-positive population dynamics using  
87 immunofluorescent microscopy (Supplementary Figure 1a,b). We did not detect  $\gamma$ H2AX-positive  
88 nuclei after only four days off dox, suggesting that one week is the earliest time point at which this  
89 population appears. To validate DNA damage response pathways were active in these nuclei, we

90 confirmed co-immunoreactivity for phosphorylated ATM kinase (pATM) (Supplementary Figure  
91 1c,d).

92 We found that all  $\gamma$ H2AX-positive nuclei stained positively for CamkIIa, a marker of excitatory  
93 neurons (Supplementary Figure 1e,f). Interestingly, at the two week time point, only  $57.37 \pm 8.822$   
94 % of  $\gamma$ H2AX-positive nuclei also stained positive for NeuN, a general marker for forebrain neurons  
95 (Supplementary Figure 1e,g). Degradation of neuron cell type identity is observed within aging  
96 and Alzheimer's disease patients<sup>31,32</sup>, and loss of NeuN expression has been proposed to be an  
97 indicator of declining neuronal health<sup>33</sup>. Indeed, reduced NeuN expression or reduced NeuN  
98 immunoreactivity is an established feature of neuronal damage<sup>34-37</sup>. Furthermore,  $\gamma$ H2AX-positive  
99 nuclei did not overlap with markers of microglia (Iba1), astrocytes (GFAP), or oligodendrocytes  
100 and oligodendrocyte precursor cells (Olig2), indicating that they were not of glial origin  
101 (Supplementary Figure 1h,i). Thus, we classified nuclei based on their NeuN and  $\gamma$ H2AX  
102 immunoreactivity. This resulted in four distinct populations:  $\gamma$ H2AX-negative NeuN-positive  
103 ("Baseline" neurons),  $\gamma$ H2AX-positive NeuN-positive (Stage 1 neurons),  $\gamma$ H2AX-positive NeuN-  
104 negative (Stage 2 neurons), and  $\gamma$ H2AX-negative NeuN-negative (putative non-neuronal cells,  
105 which we refer to as "Other") (Supplementary Figure 1g). We used fluorescence activated nuclei  
106 sorting (FANS) followed by bulk RNA sequencing to transcriptionally profile each population  
107 (Figure 1c). All nuclei were collected for sequencing at the two-week time point, which was when  
108 we observed the peak density of  $\gamma$ H2AX-positive nuclei.

109 Both Stage 1 and Stage 2 populations expressed more p25 transgene compared to other populations  
110 (Supplementary Figure 1j). CK-p25 mice exclusively express p25 in excitatory forebrain neurons,  
111 as it relies on the expression of tTA driven by the CamkII promoter. Because the p25 transgene is  
112 fused to GFP, we performed staining to validate this finding. We found that  $85.74 \pm 0.055$  % of

113  $\gamma$ H2AX-positive cells, regardless of NeuN immunoreactivity, were also GFP-positive  
114 (Supplementary Figure 1k,l). To verify Stage 2 neuronal identity independent of transgene  
115 expression, we also stained for Neurod1, a neuronal transcription factor. We found that  $81.96 \pm$   
116  $0.046$  % of  $\gamma$ H2AX-positive cells stained positively for Neurod1, regardless of NeuN  
117 immunoreactivity (Supplementary Figure 1m,n). Together, our neuron marker and transgene  
118 expression analysis indicated that both Stage 1 and Stage 2 populations were likely excitatory  
119 neurons engaged in a DSB response.

### 120 **Differential gene expression in DSB-bearing neurons.**

121 We performed two differential expression analyses to characterize gene expression changes in  
122 these populations: Stage 1 vs. CK-p25 Baseline, and Stage 2 vs. CK-p25 Baseline. Large  
123 transcriptional changes were observed in both contrasts. 3,031 upregulated and 717 downregulated  
124 transcripts were identified in Stage 1, and 5,055 upregulated and 3,792 downregulated transcripts  
125 were identified in Stage 2 ( $\log_2$  fold change  $\geq 1$ , adjusted p-value  $< 0.05$ ) (Supplementary Figure  
126 2a-c). Gene set enrichment analysis (GSEA)<sup>38</sup> revealed that both Stage 1 and Stage 2 neurons  
127 displayed a significant enrichment for genes implicated in DSB repair, apoptotic signaling, and  
128 cell cycle, and a significant reduction in synaptic function processes (Figure 1d). These pathways  
129 were previously found deregulated in both the CK-p25 mouse and AD human brain  
130 tissue<sup>9,26,29,39,40</sup>.

131 Remarkably, we also found that a number of innate immune pathways were enriched in Stage 1  
132 and Stage 2 neurons. This included gene ontology terms ‘Senescence-Associated Secretory  
133 Phenotype (SASP)’, ‘cytosolic sensors of pathogen-associated DNA’, and ‘positive regulation of  
134 innate immune response’ (Figure 1d). Upon closer inspection, we observed an enrichment of genes

135 linked to DSB-mediated activation of SASP signaling, particularly in Stage 2 neurons. This  
136 included nucleic acid sensors such as *Cgas* and *Zbp1*, NFkB subcomponents *Rela* and *Relb*, SASP  
137 factors *Il6*, *Il15*, *Ccl2*, *Cxcl10*, and interferon stimulated genes *Isg15* and *Ifitm3* (Figure 1e).  
138 Notably, a number of these genes are expressed in neurons following viral infection<sup>23,24</sup>. These  
139 genes are also classic hallmarks of senescence, suggesting that DSB accumulation elicits senescent  
140 and anti-viral-like responses in neurons.

141 Because the CK-p25 model is characterized by the development of type-I interferon-reactive  
142 microglia specifically by two weeks induction<sup>26</sup>, we wanted to determine if DSB-bearing neurons  
143 express cytokines before microglia. To do this, we performed RNAscope multiplexed fluorescent  
144 in-situ hybridization in the CK-p25 cortex after one and two weeks of induction. We focused our  
145 profiling on *Cxcl10* and *Ccl2* because these pro-inflammatory chemotactic molecules were highly  
146 expressed in Stage 2 neurons and are known to be secreted by neurons upon viral infection<sup>23,41-44</sup>.  
147 We also performed RNAscope for the excitatory neuron marker *Camk2a* to again confirm if  
148  $\gamma$ H2AX-positive nuclei were of neuronal origin. In agreement with our RNAseq and flow  
149 cytometry data,  $98.81 \pm 1.19\%$  of  $\gamma$ H2AX-positive nuclei were also *Camk2a*-positive  
150 (Supplementary Figure 2d). This high positivity rate reveals that  $\gamma$ H2AX-positive nuclei are nearly  
151 exclusively neurons. RNAscope analysis also revealed that DSB-bearing neurons were the only  
152 cells to express *Cxcl10* and *Ccl2* at the one-week time point. In contrast, *Cxcl10* and *Ccl2* gene  
153 expression was highly enriched in other cell types at the two-week time point (Figure 1f,  
154 Supplementary Figure 2e). This indicated that expression of these chemokines in  $\gamma$ H2AX-positive  
155 neurons precedes their expression in glial cells, and that cytokine secretion from DSB-bearing  
156 neurons may be an early mechanism of glial cell recruitment and activation in the CK-p25 brain.



157 To identify the master regulators of DSB-associated neuronal immune signaling, we performed  
158 transcription factor enrichment analysis using Enrichr<sup>45-47</sup>. A subset of immune pathway genes  
159 was extracted from the significantly upregulated genes in Stage 2 neurons for analysis. The overlap  
160 between this immune gene module and transcription factor target genes was then calculated.  
161 Multiple subunits of the NFkB complex were consistently enriched across Enrichr transcription  
162 factor libraries, including Rel $\alpha$ , Nfkb1, and Relb (Supplementary Table 1). Notably, the NFkB  
163 transcription factor plays a well-established role in SASP activation and the DSB response<sup>19,20,22</sup>.  
164 We chose to focus on Rel $\alpha$ , also known as p65, because it is a core member of the canonical NFkB  
165 complex, and it was most frequently enriched in the Enrichr analysis. We stained for p65 in two-  
166 week CK and CK-p25 cortices. NFkB is normally sequestered in the cytosol, but translocates to  
167 the nucleus to form an active complex upon cellular insult. Nuclear p65 intensity was significantly  
168 higher in  $\gamma$ H2AX-positive neurons compared to other  $\gamma$ H2AX-negative cells (Figure 1g),  
169 supporting evidence of increased NFkB transcriptional activity.

#### 170 **Single cell RNA-sequencing of DSB-bearing neurons.**

171 Notably, inflammatory gene expression was lower in Stage 1 neurons compared to Stage 2 neurons  
172 (Figure 1e), and more Stage 1 neurons were identified at the one-week time point compared to  
173 Stage 2 neurons (Supplementary Figure 2f,g). This suggested that the Stage 2 population may  
174 develop after Stage 1, which aligned with our initial prediction when defining these distinct cellular  
175 states based on NeuN-reactivity. To better understand the relationship between Stage 1 and Stage  
176 2 neurons, we performed single nucleus RNA-sequencing on each FANS-gated population at both  
177 one and two-week timepoints (Figure 1c). A total of 1,357 single nucleus libraries were prepared  
178 using SMARTseq2 chemistry. Following quality control measures (see methods), 889 libraries  
179 remained for downstream analysis (Figure 1h, Supplementary Figure 3a). Cells were classified

180 into major cell type clusters based on marker gene expression, resulting in the identification of 521  
181 excitatory neurons, 71 inhibitory neurons, 131 oligodendrocytes, 33 oligodendrocyte precursor  
182 cells (OPCs), and 50 microglia. We did not detect any astrocytes.

183 Remarkably, the majority of Stage 2-gated nuclei formed their own cell type cluster (Figure 1h).  
184 While we did identify 13 Stage 2-gated nuclei in microglia and oligodendrocyte clusters, all of the  
185 nuclei in question came from one CK-p25 mouse (Supplementary Figure 3b,c). None of the other  
186 five CK-p25 mice had Stage 2-gated nuclei fall into glial clusters. Combined with our previous  
187 cell type immunostaining analysis (Supplementary Figure 1h,i), we concluded that the immune  
188 signature identified in the Stage 2 population was not likely to be driven by contamination from  
189 microglia or oligodendrocytes. Compared to other neuronal clusters, the *in silico* Stage 2 cluster  
190 was significantly enriched for the FANS-gated Stage 1 and Stage 2 gene signatures  
191 (Supplementary Figure 3d). Interestingly, the Stage 2 cluster expressed only moderate levels of  
192 the excitatory neuron cluster markers *Camk2a*, *Gria1*, and *Syt2*, and lacked marker genes of other  
193 canonical cell types such as inhibitory neurons (*Gad1*, *Gad2*), astrocytes (*GFAP*), microglia  
194 (*Cd33*, *Csf1r*), oligodendrocytes (*Plp1*, *Mbp*), and OPCs (*Bcan*). Instead, the Stage 2 cluster  
195 expressed marker genes indicative of senescence, including *Cdkn1a*, and *Ubb* (Figure 1i). These  
196 distinctive cell type markers further suggested to us that the Stage 2 cluster represented a  
197 population of DSB-bearing neurons engaged in a senescence-like inflammatory response.

198 To further examine Stage 1 and Stage 2 cell type heterogeneity, we subclustered all neuronal cells.  
199 This resulted in the identification of four excitatory neuron subclusters (Ex0-3), and two inhibitory  
200 neuron subclusters (In0, In1) (Figure 1h). Stage 1 cells were enriched in subclusters Ex2 and Ex3  
201 compared to Ex0 and Ex1 (Supplementary Figure 3c). Subclusters Ex2 and Ex3 were also marked

202 by DNA repair-associated genes, such as *Hjurp*, *Lig1*, and *Zgrfl*, further suggesting that Ex2 and  
203 Ex3 cells were engaged in a DSB repair response (Figure 1i).

204 Interestingly, these DNA repair-associated genes were not expressed in the Stage 2 cluster.  
205 Combined with the enrichment for the classical senescence marker *Cdkn1a*, this suggested that  
206 Stage 2 cells may be engaged in a later-stage response to DSBs. This motivated us to perform  
207 trajectory analysis. The single cell analysis package Monocle3<sup>48-50</sup> was used to order cells from  
208 subclusters Ex0,1,2,3 and Stage 2 along a pseudotime, which was generated through a learned  
209 trajectory of subcluster gene expression differences (Figure 1j). Both CK and CK-p25 cells were  
210 used for this analysis. Next, we identified genes that changed as a function of pseudotime. We  
211 observed sequential enrichment of Stage 1 and Stage 2 gene signatures along pseudotime (Figure  
212 1k). The expression of Stage 2 signature genes specifically involved in immune response  
213 (Immune) were also enriched at the end of pseudotime (Figure 1k). We found that genes associated  
214 with neuronal identity such as *Gria2* and *Kalrn* were most highly expressed at the beginning of  
215 the trajectory (Figure 1j). Meanwhile, genes associated with DNA repair like *Hjurp*, *Lig1*, and  
216 *Nek3* peaked along the middle, and *Cdkn1a* expression peaked at the end of the trajectory. We also  
217 observed late-stage expression of *ApoE*, supporting previous observations that *ApoE* expression  
218 increases in neurons following injury<sup>51</sup>.

### 219 **DSBs elicit innate immune signaling in neurons.**

220 To test if this late-stage DSB response signature is triggered by DSBs or represents a unique  
221 response mounted by CK-p25 mice, we treated murine primary neuron cultures with 50uM  
222 etoposide (ETP). ETP produces DSBs by inhibiting topoisomerase-II function, thus preventing the  
223 re-ligation of cleaved DNA-TopII complexes (Figure 2a). This dose of ETP was consistent with

224 previous studies that used ETP to investigate DSB-elicited immune activity *in vitro*<sup>52</sup>. We also  
225 performed cell type immunostaining analysis to assess the cell type composition of our primary  
226 cultures. 82.87% of cells were identified as mature neurons (NeuN-positive), and another 9.31%  
227 were neural precursor cells (Nestin-positive), (Supplementary Figure 4a). A trace number of cells  
228 were also identified as astrocytes (GFAP-positive, 2.46%) and oligodendroglia (Olig2-positive  
229 Nestin-negative, 1.35%).

230 RNA sequencing was performed to profile the transcriptional changes occurring in primary  
231 neurons after ETP treatment (Figure 2b). There was a significant upregulation of 7,532 transcripts  
232 and downregulation of 7,106 transcripts compared to vehicle-treated control neurons (DMSO)  
233 (adjusted p-value<0.05) (Supplementary Figure 4b-d). Notably, GSEA revealed that biological  
234 pathways mediating senescent and antiviral activity such as ‘interferon alpha response,’ and ‘il6  
235 jak stat3 signaling,’ were enriched in ETP-treated cultures (Figure 2c). Furthermore, many of the  
236 cytokines upregulated in Stage 2 neurons were also upregulated in ETP-treated neurons, including  
237 *Ccl2*, *Cxcl10*, *Cxcl16*, and *Il6* (Supplementary Table 2). Stage 1 and Stage 2 gene signatures were  
238 both significantly enriched (p=0.00064 & p=0.0081 respectively) (Figure 2d, Supplementary  
239 Figure 4e). To perform a more detailed comparison of Stage 1 & 2 signature genes to ETP DEGs,  
240 we generated a Venn-Diagram (Figure 2e). 11.87% of all DEGs (total DEGs from all datasets)  
241 were shared between ETP, Stage 1 and Stage 2 conditions. This overlap was enriched for DNA  
242 damage repair genes such as *Parp10*, *Tdp2*, *Fanca*, and *Rad54l*. A further 12.87% of all DEGs  
243 were shared between ETP and Stage 2 conditions. This overlap was enriched for immune genes  
244 such as *Rela*, *Nfkb1a*, and *Irf1*.

245 To confirm immune genes were expressed by neurons and not by other trace cell types in our  
246 primary cultures, we performed RNAscope for *Ccl2* and the gene encoding NeuN, *Rbfox3*. Cells

247 that were *Rbfox3*-positive had significantly more *Ccl2* puncta than *Rbfox3*-negative cells  
248 (Supplementary Figure 4f). p65 nuclear intensity was also significantly increased in ETP-treated  
249 neurons (Figure 2a). A NeuN co-stain was used to confirm p65 activation was derived from  
250 neurons.

251 We also used an independent method of DSB induction in neurons by treating primary cultures  
252 with 10 Gy of X-ray irradiation (Figure 2f). After a 24-hour recovery period, we performed RT-  
253 qPCR to assess the mRNA levels of the Stage 2 marker gene *Cdkn1a*, and the antiviral signaling  
254 genes *Ccl2* and *Cxcl10*. 10 Gy of X-ray irradiation significantly increased the expression of all  
255 three of these genes (Figure 2g).

#### 256 **A DSB-associated immune signature is conserved in human neurons.**

257 We next sought to determine if signatures of DSB-bearing neurons can also be detected in the  
258 human brain. First, we used the Stage 2 gene signature to identify neurons with DSB-associated  
259 immune activation in a previously published snRNA-seq dataset of individuals with and without  
260 AD pathology (Figure 3a)<sup>53</sup>. We assessed Stage 2 gene expression in all major brain cell types:  
261 excitatory neurons, inhibitory neurons, astrocytes, oligodendrocytes, oligodendrocyte precursor  
262 cells, and microglia. For each cell type, genes were ranked based on their expression and  
263 correlation to ‘global pathology,’ a variable quantifying three major AD pathologies: neuritic  
264 plaques, diffuse plaques, and neurofibrillary tangles<sup>54</sup>. Genes positively correlated with global  
265 pathology for each cell type were then sampled for the enrichment of Stage 2 genes (Figure 4b).  
266 The strongest enrichment of Stage 2 genes was identified in excitatory neurons ( $p=8.7E-19$ ), and  
267 inhibitory neurons ( $p=7.7E-7$ ). Astrocytes and oligodendrocytes were also found to have a  
268 significant enrichment of Stage 2 genes correlating with global pathology, but to a much lesser

269 extent (Figure 4b), (Bonferroni adjusted p-value < 0.01). Therefore, while we cannot exclude the  
270 possibility that human astrocytes and oligodendrocytes may carry some disease-associated  
271 enrichment for Stage 2 genes, the Stage 2 signature is largely driven by neurons in this dataset.  
272 When assessing the Stage 2 genes positively correlated with global pathology in excitatory  
273 neurons, we again observed an enrichment of immune-related biological pathways, including the  
274 genes Ccl2-like receptor (*CCRL2*), *CD74*, *CXCL16*, and *APOE* (Figure 4c,d).

275 To validate the enrichment of DSB-bearing neurons identified in our snRNA-seq analysis, we  
276 sorted  $\gamma$ H2AX-positive and  $\gamma$ H2AX-negative NeuN-positive and NeuN-negative nuclei from the  
277 postmortem temporal cortex of 6 individuals, and then performed bulk RNA sequencing (Figure  
278 4e, Supplementary Figure 5a-c). These individuals were part of the Massachusetts Alzheimer's  
279 Disease Research Center (MADRC) cohort, and were divided by Braak score as either AD (Braak  
280 4-6), or non-AD (Braak 1-3). Age, sex, and other biological variables for each individual are  
281 available in Supplementary Table 3. To assess the cell type specificity of our sorted populations,  
282 we examined the expression of several cell type marker genes (Supplementary Figure 5d-f). Unlike  
283 the Stage 2 nuclei from the CK-p25 mice,  $\gamma$ H2AX-positive NeuN-negative nuclei from the human  
284 brain were enriched for glial markers (Supplementary Figure 5e,f). This indicated to us that human  
285 glial cells also accumulate DSBs, and that bulk  $\gamma$ H2AX-positive NeuN-negative nuclei were likely  
286 to contain a heterogenous population of many different cell types. Thus, to ensure we were  
287 analyzing neuronal gene expression, we focused our analysis on  $\gamma$ H2AX-positive NeuN-positive  
288 nuclei.

289 We assessed Stage 1 and Stage 2 gene signature activity in NeuN-positive nuclei from AD and  
290 non-AD human brains (Figure 4f).  $\gamma$ H2AX-positive neurons displayed modest enrichment for the  
291 CK-p25 Stage 1 and Stage 2 genes (p=0.31 and p=0.04 respectively) (Figure 4g). Comparing

292 samples by AD status and  $\gamma$ H2AX status further revealed that Stage 1 and Stage 2 gene activity  
293 was markedly enriched in  $\gamma$ H2AX-positive neurons from AD individuals ( $p=0.0075$  and  $p=0.0021$ ,  
294 respectively) (Figure 4h,i). Furthermore, when contrasting all  $\gamma$ H2AX-positive neurons against all  
295  $\gamma$ H2AX-negative neurons, we found that the average  $\log_2$  fold change values for both Stage 1 and  
296 Stage 2 gene sets were positive, and significantly higher than the average  $\log_2$  fold change values  
297 for all other genes (Supplementary Figure 5g). We also assessed the transcriptional similarity  
298 between human  $\gamma$ H2AX-positive neurons and ETP-treated primary neurons. Again, we found  
299 striking similarities between the DSB signature produced in the human brain, and the DSB  
300 signature generated by ETP treatment of primary neurons (Supplementary Figure 5h).

301 To further verify the enrichment of immune activation in DSB-bearing neurons from brains with  
302 AD pathology, we used another cohort of AD brain tissue to assess nuclear p65 expression in  
303 NeuN-positive neurons with high versus low burdens of DSBs. We acquired 4 prefrontal cortex  
304 tissue samples from individuals belonging to the Religious Orders Study cohort. All individuals  
305 analyzed exhibited AD pathology, described in Supplementary Table 4. To bin neurons by DSB  
306 burden, we analyzed  $\gamma$ H2AX expression in NeuN-positive nuclei. The median  $\gamma$ H2AX expression  
307 was calculated for each brain, and used to split neurons into the high or low DSB condition  
308 (Supplementary Figure 6a). Neurons with high DSB burden consistently expressed higher levels  
309 of nuclear p65 compared to neurons with low DSB burden (Figure 3j,k, Supplementary Figure 6b).

310 In summary, through the analysis of an independent snRNA-seq dataset, FANS RNA-sequencing,  
311 and immunohistochemistry, we found that SASP and antiviral-like pathways were active in human  
312 DSB-bearing neurons. Furthermore, this neuronal immune signature was further amplified in the  
313 context of AD pathology, suggesting that it may serve a functional role in disease-associated  
314 neuroinflammation.

315 **DSB-bearing neurons stimulate glial activation.**

316 We have previously published an in-depth characterization of reactive microglia in CK-p25 mice  
317 using snRNA-seq<sup>26</sup>. We wondered if these microglia were responding to immune signaling from  
318 DSB-bearing neurons. To address this, we performed  $\gamma$ H2AX immunostaining followed by spatial  
319 transcriptomics on two-week induced CK-p25 brains (Figure 5a). The capture areas of 10X Visium  
320 spatial transcriptomics slides are large enough to encompass the transcriptional profile of 3-5 cells  
321 in mouse brain tissue. Therefore, we hypothesized that capture areas with  $\gamma$ H2AX signal would  
322 also contain transcripts from nearby microglia. First, we identified 23 spatial clusters across three  
323 CK and four CK-p25 coronal sections (Figure 4b,c, Supplementary Figure 7a,b). Next, we used a  
324 binary classification system to identify capture areas with  $\gamma$ H2AX signal past a given threshold  
325 (See Methods, Figure 4d,e, Supplementary Figure 7c). To determine if the reactive microglia  
326 characterized in Mathys et al., 2017 were enriched in  $\gamma$ H2AX-positive capture areas, we performed  
327 a differential comparison between all  $\gamma$ H2AX-positive capture areas and all  $\gamma$ H2AX-negative  
328 capture areas. Using GSEA, we identified a robust enrichment of the microglia signature (1,383  
329 significantly upregulated genes in reactive microglia compared to homeostatic microglia) within  
330  $\gamma$ H2AX-positive capture areas compared to  $\gamma$ H2AX-negative capture areas (Supplementary Figure  
331 8a). This indicated that overall, the reactive microglia signature characterized in Mathys et al.,  
332 2017 was significantly associated with  $\gamma$ H2AX-positive neurons.

333 By mapping the density of  $\gamma$ H2AX-positive capture areas across all spatial clusters, we further  
334 prioritized distinct spatial clusters enriched for  $\gamma$ H2AX-positive capture areas (Figure 4d,  
335 Supplementary Figure 8b). We focused on spatial clusters with  $\gamma$ H2AX-positive capture areas  
336 comprising 20% or more of total capture areas (Supplementary Figure 8b). This included clusters  
337 16 and 18, which corresponded to CA1,2,3 and the dentate gyrus respectively, and clusters 2,5,6,7,



338 which were primarily localized to the cortex. Differential comparisons of  $\gamma$ H2AX-positive capture  
339 areas and  $\gamma$ H2AX-negative capture areas within each cluster of interest revealed a significant  
340 enrichment of the reactive microglia signature (Supplementary Figure 8a). Notably, many of the  
341 marker genes for reactive microglia displayed expression patterns that visually correlated with  
342  $\gamma$ H2AX-positive capture areas, including the galectin gene *Lgals3bp*, lipase *Lpl*, cystatin *Cst7*, and  
343 MHC Class I gene *H2-D1* (Figure 4f). Genes also enriched in DSB-bearing neurons, such as  
344 *Cxcl10* and *Ifitm3* was also closely correlated with  $\gamma$ H2AX-positive capture areas (Supplementary  
345 Figure 9). Collectively, this spatial transcriptomic analysis indicated that reactive microglia are  
346 closely associated with  $\gamma$ H2AX-positive neurons, suggesting the occurrence of neuro-immune  
347 communication between damaged neurons and microglia.

348 To determine if microglia responded to DSB-mediated immune signaling, we sought to inhibit a  
349 master regulator of immune gene expression in neurons. Our data revealed that NF $\kappa$ B transcription  
350 factor activity is increased in DSB-bearing neurons, as are the genes downstream of NF $\kappa$ B  
351 activation. Therefore, we focused on inhibiting NF $\kappa$ B transcriptional activity. To achieve this in  
352 the CK-p25 mouse, we opted for brain-wide viral delivery of shRNAs targeting p65<sup>55</sup>. We  
353 performed retro-orbital injections of PHP.eb AAV shp65-RFP or Scramble-RFP into CK-p25  
354 mice. CK control mice were injected with phosphate-buffered saline. Two weeks after injections,  
355 mice were taken off doxycycline and induced for two weeks (Figure 4g).

356 The majority of RFP co-localized with NeuN and  $\gamma$ H2AX immunoreactivity, indicating neurons  
357 were the primary targets of shRNA expression, and confirming the previously reported tropism of  
358 PHP.eb for neuronal infectivity (Supplementary Figure 10a,b)<sup>55</sup>. The reduced expression of p65 in  
359 mice was confirmed via qPCR and immunofluorescent staining (Supplementary Figure 10c-e).  
360 The number of  $\gamma$ H2AX-positive neurons remained the same between p65 knock-down (p65kd)

361 and Scramble mice (Supplementary Figure 10f,g). Next, we sorted  $\gamma$ H2AX<sup>+</sup> and  $\gamma$ H2AX<sup>-</sup> RFP<sup>+</sup>  
362 neurons from both p65kd and Scramble mice to assess changes in immune gene expression  
363 (Supplementary Figure 11a). RT-qPCR analysis revealed that a number of immune genes were  
364 downregulated in DSB-bearing neurons from p65kd mice compared to Scramble, including *Ccl2*,  
365 *Icam1*, *Il6*, and *Cxcl1* (Figure 4h). Downregulation of *Ccl2* in DSB-bearing neurons was also  
366 confirmed via RNAscope (Supplementary Figure 11b,c). This indicated p65kd was able to alter  
367 neuron immune gene signatures.

368 To determine if suppressing neuron immune genes rescued microglial activation, we performed  
369 immunofluorescent staining with the microglia marker Iba1. We found that p65kd mice showed a  
370 reduced number of microglia (Figure 4i), which was confirmed through flow cytometry analysis  
371 of PU.1-positive nuclei from the entire cortex (Supplementary Figure 11d,e). We also found that  
372 microglia soma area was significantly reduced, but differences in branch length and end points  
373 were not statistically significant (Figure 4i). These data show that suppressing neuron immune  
374 signaling significantly affects the number and morphology of microglia.

375 To determine if changes in microglial number and morphology were accompanied with changes  
376 in gene expression, we performed RNA sequencing on sorted PU.1-positive nuclei from CK  
377 control, CK-p25-scramble, and CK-p25-p65kd cortex (Figure 4g, Supplementary Figure 11d).  
378 Differential analysis comparing microglia from p65kd and Scramble cortices revealed the  
379 upregulation of 627 transcripts and downregulation of 160 transcripts (Figure 4j, Supplementary  
380 Figure 11i,j). Interestingly, pathways related to synaptic activity and membrane organization were  
381 significantly upregulated in microglia from p65kd mice. This included calcium channels *Cacna1g*,  
382 *Cacna1c*, and *Cacnb2*, and sodium channel *Scn1a*, suggesting p65kd microglia may return to a  
383 more homeostatic state embodied by CK microglia (Figure 4j). In contrast, the genes that were

384 downregulated in microglia from p65kd mice were involved in cell killing and antigen processing,  
385 such as *H2-Q2*, *Lag3*, *Ccr5*, and *Ccr2*. Notably, the *Ccr2* gene encodes the receptor for Ccl2,  
386 further implying an alteration of the Ccl2-Ccr2 axis (Figure 4k,l). We also observed a  
387 downregulation of genes related to lipoprotein processing (Figure 4k,l). Together, these results  
388 suggest that neuron immune signaling disrupts microglia homeostatic activity, and activate cell  
389 killing and antigen processing mechanisms in microglia.

390 Finally, to determine if specific cytokines expressed and secreted by DSB-bearing neurons play a  
391 role in microglia activation, we transitioned to our *in vitro* ETP model of DNA damage. First we  
392 wanted to understand how conditioned media from ETP-treated neurons affect microglia  
393 morphology. To do this, we generated organotypic acute brain slice cultures from Cx3cr1-GFP  
394 mice, which express GFP in all microglia. After ETP treatment and washout with PBS, neurons  
395 recovered in fresh media for 24 hours. This conditioned media was then collected and applied to  
396 Cx3cr1-GFP brain slices for 6 hours (Figure 5a). The conditioned media from ETP-treated neurons  
397 reduced microglia branch length (Figure 5b,c), but did not significantly affect the number of  
398 endpoints per microglia (Figure 5d). We also observed increased soma area (Figure 5e). Treating  
399 primary neurons with an NFkB activation inhibitor before and during ETP treatment significantly  
400 reduced the soma area of Cx3cr1-GFP-positive microglia, and increased branch length and end-  
401 points (Figure 5b-e). Conditioned media from ETP-treated neurons did not elicit a robust  
402 difference in the number of microglia analyzed per image (Figure 5f). These data further  
403 demonstrate NFkB activity as a significant mediator of immune signaling in DSB-bearing neurons.  
404 Notably, conditioned media from ETP-treated neurons was significantly enriched for Cxcl10 and  
405 Ccl2 (Figure 5g,h). Furthermore, the NFkB activation inhibitor reduced the concentration of these  
406 cytokines (Figure 5g,h). Previously, we found that DSB-bearing neurons are the first cells to

407 express Cxcl10 and Ccl2 in the CK-p25 cortex (Figure 1f, Supplementary Figure 2e). These  
408 cytokines induce the migration of microglia and macrophages to sites of viral infection, traumatic  
409 brain injury, and gliomas, suggesting that they may be primary constituents of immune signaling  
410 in DSB-bearing neurons<sup>23,43,44,56,57</sup>. To determine if they played a role in DSB-mediated microglia  
411 activation, we immunodepleted Ccl2 or Cxcl10 from conditioned media (Figure 5i). Both Ccl2  
412 and Cxcl10 depletion increased branch length and end-points per microglia compared to IgG  
413 control depletion (Figure 5j,k,l). Interestingly, Ccl2 depletion reduced microglia soma area, but  
414 Cxcl10 depletion did not (Figure 5m). Neither immunodepletion had an effect on microglia  
415 number (Figure 5n). Combined, this suggests that while both Ccl2 and Cxcl10 elicit morphological  
416 changes in microglia, they may play differential roles in microglia activation. Notably, both Ccl2  
417 and Cxcl10 are upregulated in aging and AD pathogenesis, suggesting their signaling activity via  
418 DSB-bearing neurons could have significant effects on neuroinflammation<sup>44,58,59</sup>. Together, our  
419 data indicate Ccl2 and Cxcl10 play important roles in recruiting and activating microglia to  
420 neurons burdened with DSBs. This establishes a novel role for neuronal communication with  
421 microglia in the context of age-associated neurodegenerative disease, and uncovers a new facet of  
422 DSB toxicity in mature postmitotic neurons.

## 423 **Discussion**

424 Substantial evidence supports a causal role for microglia and neuroinflammation in AD  
425 pathogenesis<sup>29,60,61</sup>. For example, many AD risk genes and genomic loci are most active in  
426 microglia<sup>62-64</sup>, and reactive microglia are thought to create a cytotoxic environment for neurons  
427 and exacerbate neurodegeneration<sup>65-68</sup>. Here, we provide evidence that neurons participate in this  
428 inflammatory signaling as well. Specifically, upon the accumulation of DSBs, neurons are able to  
429 engage microglia through the secretion of proinflammatory factors, thus facilitating

430 neuroinflammation and disease progression. This is a previously undefined role for neurons in the  
431 context of neurodegenerative disease, and provides a mechanistic link between genomic fragility  
432 and senescence in neurons and microglia activation.

433 Interestingly, the activation of inflammatory signaling in DSB-bearing neurons corresponds with  
434 a progressive erosion of cell identity. Using single-nuclei RNA-seq, we find that DSB-bearing  
435 neurons engage DNA repair pathways first, but transition to immune gene expression at later stages  
436 of genome toxicity. These cells are most enriched for senescent markers, such as *Cdkn1a* and *Ubb*,  
437 rather than neuronal markers. The age-dependent erosion of neuronal identity has been observed  
438 in both sporadic and familial Alzheimer's disease patients, and coincides with the activation of a  
439 number of biological pathways identified in our study, including DNA damage response, cell-  
440 cycle re-entry, and NF- $\kappa$ B signaling<sup>31,32</sup>. Interpreted in the context of the present study, these  
441 observations could suggest that the age-associated accumulation of DSBs degrades chromatin  
442 integrity, ultimately resulting in the activation of immune signaling that engage microglia.

443 The SASP and canonical antiviral response is activated through the detection of non-endogenous  
444 nucleic acids within the cytosol. Thus, it is likely that loss of nuclear and genomic integrity may  
445 lead to the release of DNA fragments in DSB-bearing neurons. In fact, we observed increased  
446 expression of nucleic acid sensors in DSB-bearing neurons, including cGAS, which plays a  
447 significant role in innate immune activation associated with senescence<sup>18</sup>. Nevertheless, many  
448 other mechanisms may be at play, including de-repression of transposable elements<sup>69</sup>, epigenetic  
449 drift<sup>14</sup>, and ATM-mediated NF $\kappa$ B transcription<sup>19,20</sup>. There is also evidence that nucleic acids  
450 released from mitochondria play roles in neuron immune gene expression<sup>70</sup>. It remains to be  
451 addressed whether DSB-induced immune gene expression is a product of age-associated decline

452 in DNA repair, or whether multiple cellular functions that are also known to decline with age  
453 engage immune signaling as a convergent mechanism of neuronal distress.

454 We identified NFkB as a major regulator of immune gene expression in DSB-bearing neurons  
455 from both CK-p25 mice, primary neurons, and postmortem human brain. In addition, we found  
456 that suppression of NFkB activity through p65 knock down or small molecule inhibition primarily  
457 in neurons was sufficient to reduce activated microglia morphology and gene expression. NFkB  
458 has been previously identified as a therapeutic target for AD, albeit in the context of microglia and  
459 astrocytes<sup>71</sup>. Our results now indicate that this transcription factor plays a pivotal role in DSB-  
460 bearing neurons as well. Importantly, in rodent models of learning and memory, NFkB activity in  
461 neurons is neuroprotective. Suppression of NFkB in forebrain excitatory neurons impairs spatial  
462 learning and neuronal plasticity<sup>72</sup>, and exacerbates cell death following exposure to neurotoxic  
463 stimuli<sup>73</sup>. Therefore, the primary role of NFkB may regulate healthy neuronal function in times of  
464 homeostasis, but it can also orchestrate immune activation in response to cell stressors.

465 Finally, we identify Ccl2 and Cxcl10 as primary signaling molecules secreted from DSB-bearing  
466 neurons to recruit and activate microglia. In the CK-p25 model, DSB-bearing neurons are the first  
467 cell type to express Cxcl10 and Ccl2. Other cell types express these chemokines at a later  
468 timepoint, presumably in response to DSB-bearing neurons. Furthermore, spatial transcriptomics  
469 reveal that signatures of reactive microglia are closely associated with  $\gamma$ H2AX-positive neurons,  
470 suggesting that DSB-bearing neurons are hubs for neuro-immune communication. Notably,  
471 increased levels of both of these cytokines are implicated in the pathogenesis of AD, and affect  
472 blood brain barrier permeability to aid the infiltration of peripheral monocytes<sup>23,43,74,75</sup>. However,  
473 manipulation of either signaling axis seem to have varying effects on AD pathology. For example,  
474 Ccr2 deficiency in murine models of AD aggravate amyloid pathology and cognitive decline, but

475 Ccl2 overexpression seems to also increase amyloid deposition<sup>42,76,77</sup>. Another study demonstrates  
476 that deficiency of the Cxcl10 receptor Cxcr3 reduces amyloid deposition and behavioral deficits<sup>78</sup>.  
477 These findings suggest that Ccl2 and Cxcl10 are crucial for effective microglia recruitment and  
478 activation, but imbalance in these signaling axes have detrimental effects on cognition and  
479 pathology clearance.

480 As a whole, we leveraged bulk, single-nuclei, and spatial transcriptomic techniques in parallel with  
481 *in vitro* and *in vivo* manipulations of NFkB signaling to characterize DSB-bearing neurons and  
482 their relationship with microglia in the context of age-associated neurodegenerative disease. We  
483 demonstrate that DSB accumulation elicits senescent and antiviral-like signaling in neurons, which  
484 recruits and activates microglia in an NFkB-dependent manner. Our data posit that neurons play  
485 meaningful roles in neuroinflammation, which historically was largely thought to be driven solely  
486 by glial cells. Crucially, this axis of neuron-microglia communication is mediated by DNA damage  
487 accumulation in neurons, revealing that two hallmarks of Alzheimer's disease, genome fragility  
488 and neuroinflammation, are mechanistically linked.

## 489 **Methods**

### 490 **Fluorescence-activated nuclei sorting**

491 Frozen cortices were disrupted with a handheld homogenizer in ice-cold PBS with protease  
492 inhibitors (cat no. 11836170001, Roche, Basel Switzerland) and RNase inhibitors (cat no.  
493 EO0382, Thermo Fisher Scientific, Waltham MA). Samples were fixed with 1%  
494 paraformaldehyde for 10 minutes at room temperature, then quenched with 2.5M glycine for 5  
495 minutes. Nuclei were isolated through dounce-homogenization followed by filtration with a 70uM  
496 cell strainer (cat no. 21008-952, VWR, Radnor PA). The following antibodies were used to  
497 immunotag nuclei: anti-H2A.X-Phosphorylated (Ser139) antibody conjugated to APC (cat no.  
498 613416, BioLegend, San Diego CA), anti-ATM-phospho (Ser1981), antibody conjugated to PE  
499 (cat no. 651203, BioLegend, San Diego CA), anti-NeuN antibody conjugated to Alexa Fluor 488  
500 (cat no. MAB377X, EMD Millipore, Burlington MA), anti-PU.1 antibody conjugated to Alexa  
501 647 (cat no. 2240S, Cell Signaling Technology, Danvers MA), anti-RFP antibody (cat no. 600-  
502 401-379, Rockland Antibodies and Assays, Gilbertsville, PA), and anti-CaMKII- $\alpha$  (6G9) antibody  
503 (cat no. 50049S, Cell signaling Technology, Danvers MA). Antibodies were incubated with nuclei  
504 in 1% BSA/PBS at 4°C for one hour or overnight. For non-conjugated antibodies, samples were  
505 washed once with 1% BSA/PBS, then resuspended with 1:1000 Alexa Fluor secondary antibody  
506 (Thermo Fisher Scientific, Waltham MA) for one hour at 4°C. Samples were strained through a  
507 40um filter (21008-949, VWR) and stained with DAPI (cat no. D9542, Sigma Aldrich, St. Louis  
508 MO) before sorting. Sorting was performed on a FACS Aria at the Koch Institute Flow Cytometry  
509 Core (BD Biosciences, US). At least 50,000 nuclei of each cell type was collected for RNA-  
510 sequencing. Nuclei were sorted into 1% BSA/PBS, then spun at 2kG for 15 minutes in a cooled  
511 centrifuge (cat no. 97058-916, Epindorf North America) for downstream analysis. For single-  
512 nucleus RNA-sequencing, nuclei were not fixed. Single nuclei were sorted into a 96-well plate  
513 then transported immediately to the MIT BioMicro Center for library preparation. Flow cytometry  
514 analysis was performed using FlowJo software (Ashland, OR).

### 515 **Human $\gamma$ H2AX fluorescence-activated nuclei sorting**

516 Frozen temporal cortex tissue samples were homogenized and stained following the protocol  
517 described above. A two-week induced CK-p25 mouse sample was used to set a  $\gamma$ H2AX-  
518 positive/negative threshold for human nuclei.

### 519 **Bulk RNA sequencing**

520 For bulk RNA-sequencing of sorted nuclei, samples were treated for 15 minutes with Proteinase  
521 K at 50°C and then for 13 minutes at 80°C. RNA was extracted using Direct-zol RNA MicroPrep  
522 kit according to manufacturer's instructions (cat no. R2062, Zymo Research, Irvine CA). Purified  
523 RNA samples underwent fragment analysis at the MIT BioMicro Center. Libraries were generated  
524 from samples passing quality control (DV200 < 50%). Library generation was performed using  
525 the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian (cat no. 634412, Takara



526 Bio Inc), then submitted to the MIT BioMicro Center for quality control (fragment analysis and  
527 qPCR), followed by sequencing. Paired-end sequencing was performed using the Illumina  
528 NextSeq500 platform according to standard operating procedures.

529 For bulk RNA sequencing of etoposide-treated primary neurons, cultures were collected in Trizol  
530 LS (cat no. 10296028, Thermo Fisher Scientific, Waltham MA). mRNA was purified and extracted  
531 using Direct-zol RNA MicroPrep kit according to manufacturer's instructions. RNA was  
532 submitted to the MIT BioMicro Center for library preparation and sequencing. Libraries were  
533 prepared using NEBNext<sup>®</sup> Ultra<sup>™</sup> II RNA Library Prep Kit for Illumina<sup>®</sup> (cat no. E7770, New  
534 England Biolabs, Ipswich MA). Single-end sequencing was performed using the Illumina  
535 NextSeq500 platform according to standard operating procedures.

### 536 **Mouse Bulk RNA-seq Read cleaning and bulk RNA-Seq pipeline**

537 From the paired-end fastq files, the first three nucleotides were trimmed off the second sequencing  
538 read using cutadapt version 1.16. TrimGalore version 0.4.5 was used in paired mode to trim  
539 adapters and low-quality portions of reads. Reads were aligned using Salmon version 0.12.0 to  
540 mouse genome version GRCm38.94 and human genome version GRCh38.94. For downstream  
541 analysis, TPM files from Salmon were imported into R version 3.6.1 using tximport version 1.14.0  
542 with the option to generate estimated counts using abundance estimates scaled up to library size,  
543 and additionally scaled using the average transcript length over samples and the library size  
544 (`countsFromAbundance = lengthScaledTPM`).

### 545 **Mouse Bulk RNA-seq Differential Analysis**

546 We performed differential analysis using R version 3.6.1 and DESeq2 version 1.26.0. For each  
547 corresponding cell type and condition, we performed differential expression using only the  
548 corresponding samples. We selected genes as significant if they met the cutoff threshold (absolute  
549 value of the log<sub>2</sub> fold change > 1, adjusted p-value < 0.05).

### 550 **Mouse Bulk RNA-seq Gene Set Enrichment Analysis**

551 We used the complete set of RNA-Seq results for each differential analysis for downstream GSEA  
552 processing. Genes for which adjusted p-value could not be calculated were excluded. We ran  
553 GSEA version 3.0 in ranked list mode with default settings. The gene ontology biological  
554 pathways gene sets from Molecular Signatures Database v7.3 (MSigDB) were used for analysis.  
555 Genes were ranked by the sign of the fold change times the negative base 10 log of the adjusted p-  
556 value.

### 557 **Enrichr**

558 Significantly upregulated genes from the Stage 2 vs. Baseline contrast were filtered based on their  
559 occupation in MSigDB gene ontology biological processes containing the keyword "immune."

560 This resulted in a Stage 2 immune module comprised of 940 genes. The corresponding Entrez gene  
561 symbols were then entered in to the Enrichr website: <https://maayanlab.cloud/Enrichr/#>. The  
562 resulting transcription factor enrichment data were downloaded as tables from the following  
563 transcription factor libraries: ChEA 2016, ENCODE and ChEA Consensus TFs from ChIP-X,  
564 TRRUST Transcription Factors 2019, Enrichr Submission TF-Gene Cooccurrence, TRANSFAC  
565 and JASPAR PWMs, and ENCODE TF ChIP-seq 2015. Data are available in Supplementary Table  
566 1. More information about the Enrichr libraries can be accessed on the Enrichr website.

## 567 **Smart-seq pipeline**

### 568 **SMART-seq2**

569 Single nuclei library preparation was performed by the MIT BioMicro Center using the SMART-  
570 Seq® v4 Ultra® Low Input RNA Kit for Sequencing (Takara Bio Inc) according to manufacturer's  
571 instruction. Libraries were sequenced on a MiSeq Illumina sequencer according to standard  
572 operating procedures.

### 573 **Read processing.**

574 We aligned 40-bp paired-end reads to the mm10 genome for each of 1,357 single nuclei from 12  
575 mice (64 cells each for 6 CK controls and an average of 162 cells in each of 6 CKp25 mice) using  
576 bwa mem (options: -k 15 -M) and filtered out improperly aligned reads and secondary alignments  
577 with samtools (options: -f 3 -F 1280). We ran HTSeq-count10 on each cell's filtered bam file to  
578 compute the cell's transcriptomic coverage over each gene's exons in vM25 GENCODE gene  
579 annotation.

### 580 **Transgene detection.**

581 We first aligned 40-bp single-end reads from each sequenced single nucleus separately with the  
582 STAR aligner6 against the b37 genome with decoy contigs using a two pass alignment (options: -  
583 -outFilterMultimapNmax 20 --alignSJoverhangMin 8 --alignSJDBoverhangMin 1 --  
584 alignIntronMin 20 --alignIntronMax 1000000). We then used Picard tools7 to revert and merge  
585 the alignment with unaligned reads and marked duplicates on the merged bam file. We identified  
586 and removed alignments on decoy contigs, sorted and fixed NM, MD, and UQ tags with Picard  
587 tools, filtered duplicates, unmapped, and non-primary alignment reads, and split reads by Ns in  
588 their CIGAR string.

### 589 **Cell type annotation**

#### 590 **Cell identities**

591 We used SCANPY11 to process and cluster the expression profiles and infer cell identities. We  
592 kept only 21,859 protein coding genes detected in at least 3 cells and filtered out 349 cells with  
593 less than 100 expressed genes, leaving 1,008 cells over the 12 mice. We used the filtered dataset

594 to calculate the low dimensional embedding of the cells (UMAP) from the log1p matrix PCA with  
595 k=50 and nearest neighbor graph with N=20 (UMAP default parameters, min\_dist=0.2), and  
596 clustered it with Leiden clustering (resolution=2), giving 17 preliminary clusters. We then  
597 manually assigned clusters based on the following 2-3 major marker genes per class: Excitatory  
598 neurons: Camk2a, Gria2, Syt1; Inhibitory neurons: Gad1, Gad2; Astrocytes: Gfap; Microglia:  
599 Cd33, Csf1r; Oligodendrocytes: Plp1, Mbp; Oligodendrocyte progenitor cells (OPCs): Bcan; Stage  
600 2: Cdkn1a, Ubb. We merged clusters sharing marker genes to obtain 7 final clusters, defining two  
601 broad neuronal subtypes (484 excitatory and 108 inhibitory cells), three glial clusters (50  
602 microglia, 131 oligodendrocytes, and 33 OPCs), 179 Stage 2 cells, and 23 cells with both high  
603 read counts and broad, non-specific marker gene expression, likely due to doublets or other sorting  
604 artifacts. The doublet cluster was removed from downstream analyses. We also identified a cluster  
605 of cells that expressed fewer than 500 genes and had high expression of mitochondrial genes. Due  
606 to the questionable quality of these cells, this cluster was also removed from downstream analysis.  
607 We further sub-annotated neuronal subtypes from neuronal clusters with distinctive expression in  
608 the original Leiden clustering, resulting in four excitatory subclusters (314 Ex0, 91 Ex1, 32 Ex2,  
609 and 47 Ex3 neurons) and two inhibitory subclusters (71 In0 and 37 In1 neurons).

#### 610 **Signature analysis on single-cells**

611 For each signature, a joint expression value was calculated as the number of reads per 10k reads  
612 in each cell coming from all of the signature's genes (genes with adjusted p-values < 0.05).  
613 Signature expression was transformed by log1p and averaged across all cells in a given neuronal  
614 subtype and mouse to obtain average signature values for plotting. We used two-sided t-tests to  
615 compare the signature expression levels of pairs of excitatory neuronal subtypes (Supplementary  
616 Figure 3f-h).

#### 617 **Trajectory analysis**

##### 618 **Pseudotime**

619 We performed pseudotime analysis using Monocle3 (v0.2.3.0) on the 349 Ex1, Ex2, Ex3, and  
620 Stage 2 neuronal populations. We normalized total counts per cell in the read count matrix to the  
621 median number of counts, log1p transformed the matrix, and regressed out the counts per gene  
622 using Monocle. We clustered the subsetted data in a new UMAP, clustered cells, learned a  
623 trajectory graph, and ordered cells by choosing the initial node as the Ex1 end of the graph to get  
624 a pseudotime across the graph. We plot the log1p read counts across the gene set as well as the  
625 generalized additive model (GAM) smoothed fits of each signature's per-cell expression values  
626 across pseudotime (Figure 2e,f).

##### 627 **Differential genes on pseudotime**

628 We used tradeSeq to detect differentially expressed genes along the pseudotime, by fitting GAMs  
629 to each gene along pseudotime with uniform weights on each cell and performing an association

630 test to test for genes with pseudotime-associated expression patterns. We found 530 significant  
631 genes. We selected a number of representative genes and plotted their smoothed fit (binned into  
632 100 bins across pseudotime and scaled) and their expression (log<sub>1p</sub> per-cell normalized counts)  
633 across the 349 pseudotime-ordered cells. We labeled each gene with the neuronal subtype closest  
634 to the pseudotime point with its peak expression (Supplementary Figure 3f).

### 635 **Ontology enrichment**

636 We created 20 tiled windows of 20 quantiles in width across cellular pseudotime, for each window  
637 selected genes whose peak smoothed expression fell into the pseudotime range, and performed  
638 GO enrichment on each window's genes using gprofiler, limiting results to terms with fewer than  
639 2,500 genes in GO and Reactome. For visualization, we manually curated 34 representative top  
640 enriched terms across all Reactome and GO enrichments (Supplementary Figure 3j).

### 641 **Human bulk RNA-seq analysis**

642 Paired-end reads were trimmed for adapters using TrimGalore  
643 (<https://github.com/FelixKrueger/TrimGalore>) and aligned to the human genome reference  
644 GRCh38/hg38 using the R software package Rsubread (Liao, Smyth, and Shi 2019). Mapped reads  
645 were summarized to gene level counts using the featureCounts function of Rsubread, considering  
646 the latest RefSeq Reference Genome Annotation for gene reference. Protein coding genes with  
647 detected counts in at least 1 sample library were retained and normalized in rpkm units.  
648 Normalization and differential expression analysis was performed using the edgeR package  
649 (Robinson, McCarthy, and Smyth 2010). All statistical analyses and plots were performed using  
650 the statistical programming language R (<http://www.r-project.org/>). Gene ontology and functional  
651 enrichment analyses were performed using gprofiler2 package (Kolberg et al. 2020).

### 652 **Human bulk gene set activity analysis**

653 Gene set activity for cell type marker genes and gene signatures identified in the Cpk25 mouse  
654 model were quantified per human bulk RNAseq sample using Gene Set Variation Analysis  
655 (GSVA) (Hänzelmann, Castelo, and Guinney 2013), as implemented in the Bioconductor package  
656 GSVA (<https://www.bioconductor.org/packages/release/bioc/html/GSVA.html>). For cell cell type  
657 signature analysis the consensus human brain cell type markers reported in (Mohammadi, Davila-  
658 Velderrain, and Kellis 2020) were used as reference. Differential gene signature activity across  
659 conditions ( $\gamma$ H2AX +/ctr, AD/noAD) and/or cell groups (NeuN+/NeuN-) was assessed using a  
660 two-sided wilcoxon rank sum test.

### 661 **Human snRNA-seq analysis**

662 Single-nucleus transcriptomic sequencing data from postmortem cortical samples (prefrontal  
663 cortex, Brodmann area 10) of 48 subjects with varying levels of AD pathology was obtained from  
664 (Mathys et al. 2019). Individual-level celltype expression profiles were computed by averaging for

665 each individual the normalized gene-expression profiles across cells of the same cell type. Average  
666 profiles were subsequently mean-centered and scaled to compute gene-wise correlation  
667 coefficients of gene expression versus individual-level measures of global AD pathology burden  
668 reported as part of the ROSMAP cohort. Briefly, global burden of AD pathology is a quantitative  
669 summary of AD pathology derived from counts of three AD pathologies: neuritic plaques (n),  
670 diffuse plaques (d), and neurofibrillary tangles (nft), as determined by microscopic examination of  
671 silver-stained slides (Mathys et al. 2019).

672 Global consistency between gene signatures observed in CKp25 mice and a neuronal-specific  
673 association between gene expression and AD pathology in human tissue was assessed statistically  
674 using a nonparametric resampling test. To test whether cell-type specific expression of CKp25  
675 Stage 2 signature genes tends to correlate with pathology in the human brain, a z-score statistic  
676 was computed to quantify the deviation of their correlation coefficient rank scores, relative to  
677 random expectation. Expected scores were estimated by randomly sampling same-sized gene sets  
678 ( $n = 1,000$  replicates). This analysis was performed for excitatory neurons, inhibitory neurons, and  
679 microglia cells independently.

#### 680 **Stage 1 and 2 signature generation**

681 Stage 1 and Stage 2 gene signatures were curated by performing differential expression analysis  
682 on the CK-p25 bulk RNAseq dataset. Stage 1 vs Baseline provided the genes for the Stage 1  
683 signature, and Stage 2 vs Baseline provided the genes for the Stage 2 signature. Only genes which  
684 met the cutoff threshold ( $\log_2$  fold change  $> 1$ , adjusted p-value  $< 0.05$ ) were retained.

#### 685 **Visium spatial transcriptomics library generation**

686 Mice were transcardially perfused with ice-cold saline, then brains were dissected and flash frozen  
687 in OCT. A cryostat was used to generate 10 $\mu$ M coronal sections of the hippocampus. These  
688 sections were applied to 10X Visium Spatial Gene Expression slides. Sections were  
689 immunostained with  $\gamma$ H2AX and DAPI following manufacturer's instructions. Sectioning and  
690 staining was performed at the MIT Hope Babette Tang (1983) Histology Core Facility. Sections  
691 were imaged immediately after staining using a Olympus FV1200 Laser Scanning Confocal  
692 Microscope at the MIT Microscopy Core Facility. Sections were then used to generate 10X Visium  
693 Spatial Gene Expression Libraries according to manufacturer's instructions at the MIT BioMicro  
694 Center. Libraries were sequenced on a NovaSeq6000 Illumina sequencer according to standard  
695 operating procedures.

#### 696 **Visium spatial transcriptomics data processing**

697 Samples were processed using Scanpy 1.7.2. The 7 sample data matrices were merged into one  
698 matrix which was then processed. The sample id and location of each capture area of the resulting  
699 matrix were saved and used for visualization. Counts were normalized (total count of 10,000 per  
700 capture area) and logarithmized (using scanpy's  $\log_{1p}$  function). The resulting counts matrix,

701 called raw normalized was used for expression visualization and differential expression analysis.  
702 For dimension resolution purposes, the raw normalized matrix was further processed: genes that  
703 were not characterized as highly variable enough were filtered out (minimum mean of 0.0125, max  
704 mean of 3, minimum dispersion of 0.5), and linear regression was performed to eliminate the effect  
705 of covariates (total\_counts, and mitochondrial genes percentage). The data was then scaled  
706 (standard scaling, max value of 10). Afterwards, PCA was performed, as well as sample-level  
707 batch correction, using Harmony. Then, a knn network was constructed for the creation of a UMAP  
708 embedding. Clusters were discovered using the leiden algorithm.

### 709 **Visium immunohistochemistry image processing**

710 Immunostaining images were first processed as shades of gray pictures. The largest  
711 autofluorescence artifacts were removed manually. The signal was then amplified and cleaned  
712 using a 85% contrast increase on each image.

713 As the immunochemistry images of the tissue align perfectly to the pictures taken for 10X Visium  
714 purposes, calibration was performed to reconstruct the capture areas grid on the immunostaining  
715 images. In that image, for each capture area, the mean signal within a circle maximizing image  
716 coverage is calculated, and recorded as the DNA-Damage signal. After standard scaling of this  
717 variable, a threshold of 0.4 standard deviation was set, to assign a capture areas as positive or  
718 negative for DNA damage.

### 719 **Visium differential expression and Mathys et al., 2017 microglia signature analysis**

720 Differential expression analysis was performed using Wilcoxon rank sum test, and the resulting p-  
721 values were corrected using Benjamini-Hochberg FDR correction. For GSEA, the package gseapy  
722 was used, with 100 permutation and the signal-to-noise method. As input, the raw normalized  
723 matrix was used, though only containing the genes considered as highly variable in the dataset.

### 724 **RT-qPCR**

725 RNA was extracted from primary tissue cultures using the RNeasy Plus mini kit (cat no. 74136,  
726 Qiagen, Hilden Germany). Reverse transcription was performed using Invitrogen SuperScript IV  
727 First Strand Synthesis System with Oligo dT primers according to the manufacturer's protocol (cat  
728 no. 18091050, Thermo Fisher Scientific, Waltham MA). cDNA was quantified with a NanoDrop  
729 spectrophotometer. qPCR was performed using a Bio-Rad CFX-96 quantitative thermal cycler (cat  
730 no. 1855195, Bio-Rad, Hercules CA) and SsoFast EvaGreen Supermix (cat no. 1725202, Bio-Rad,  
731 Hercules CA). Relative changes in gene expression were determined using the  $2^{-\Delta\Delta Ct}$  method.  
732 Cycle numbers for the gene *Gapdh* or *Rpl11* were used for housekeeping Ct values.

### 733 **Immunofluorescent microscopy**

734 Mice were transcardially perfused with ice-cold PBS, then fixed with ice-cold 4%  
735 paraformaldehyde in PBS. Dissected brains were drop-fixed overnight in 4% paraformaldehyde in

736 PBS at 4°C. Forebrains were sectioned with a vibrating microtome (Leica BioSystems, Wetzlar  
737 Germany) to generate 40 µM coronal slices. Slices were blocked for two hours at room temperature  
738 in blocking buffer (10% NGS, 0.3% Triton X-100, PBS), then incubated with primary antibody  
739 overnight at 4°C. Slices were washed 3 x 10 minutes with PBS, and Alexa Fluor Secondary  
740 antibodies (Thermo Fisher Scientific) were added at a 1:1000 dilution for 1 hour at room  
741 temperature. Slices were washed again 3 x 10 minutes with PBS, then stained with DAPI (cat no.  
742 D9542, Sigma Aldrich, St. Louis MO) and mounted onto Fisherbrand™ Superfrost™ Plus  
743 Microscope Slides (cat no. 12-550-15, Thermo Fisher Scientific, Waltham MA) with  
744 Fluoromount-G™ Slide Mounting Medium (cat no. 100502-406, VWR, Radnor PA).

745 Primary neurons cultured on cover glass (cat no. 194310012A, VWR, Radnor PA) were washed  
746 once with PBS, then fixed with 4% paraformaldehyde/PBS for 15 minutes at room temperature.  
747 Immunostaining proceeded as described.

748 Free-floating slices, at 40µm thickness from postmortem human brain blocked for 1 hour at room  
749 temperature in blocking buffer before being incubated in primary antibodies for 72 hours at 4°C  
750 with gentle rocking in blocking buffer (Anti-NeuN, Synaptic Systems cat no. 266 004, 1:500;  
751 Anti-phospho-Histone H2A.X, Millipore cat no. 05-636, 1:100; Anti-NFκB p65 Invitrogen cat no.  
752 51-0500, 1:300). Samples were then rinsed three times in 1xPBS for 5 minutes and incubated in  
753 secondary antibodies (Alexa Fluor-488, 594 or 647, ThermoFisher Scientific; 1:1,000) for 2 hours  
754 at room temperature. After 1x PBS rinse, samples were incubated in 1:10,000 Hoechst in PBS  
755 (Invitrogen cat no. H3569) followed by 2 minutes in TrueBlack Lipofuscin Autofluorescence  
756 Quencher (Biotium cat no. 23007) with 3 subsequent 1x PBS rinses before mounting and imaging.

757 Mounted samples were imaged with a Zeiss LSM 710 confocal microscope. Images were  
758 quantified using ImageJ (NIH Image Analysis) and Imaris (Oxford Instruments). At least two  
759 coronal slices were used for each mouse for image quantification. For PHP.eb AAV shp65-RFP  
760 cell-type analysis, 40 µM coronal brain sections were stained for RFP and either NeuN, Iba1,  
761 GFAP, or Olig2. First, RFP-positive cells were identified in each image. Then, the percent of RFP-  
762 positive cells that also had positive immunoreactivity for a given cell-type marker was quantified.  
763 GFAP-positive cell number and intensity were calculated using Imaris software (Oxford  
764 Instruments, UK).

## 765 **Primary Neuron Culture**

766 Cortices were dissected from E15 Swiss-Webster embryos in ice-cold HBSS (cat no. 14175103,  
767 Thermo Fisher Scientific, Waltham MA) and dissociated with papain (cat no. LS003126,  
768 Worthington Biochemical Corp., Lakewood NJ) and DNase I (cat no. 10104159001, Roche, Basel  
769 Switzerland). Cells were resuspended in plating media (Neurobasal media (cat no. 21103049,  
770 Thermo Fisher Scientific, Waltham MA), 1% Penicillin/Streptomycin Solution (cat no. 400-109,  
771 Gemini Bio-Products, Sacramento CA), 10% FBS)) and filtered through a 100 µM cell strainer  
772 (cat no. 21008-950, VWR, Radnor PA). Cell density was quantified using a Countess II Automated

773 Cell Counter (cat no. AMQAX1000, Thermo Fisher Scientific, Waltham MA), then plated on poly-  
774 D-Lysine-coated 12-well culture dishes,  $0.5 \times 10^6$ . Cultures were maintained in 5% CO<sub>2</sub> at 37 °C  
775 in a cell culture incubator. After allowing four hours for the cells to adhere to the plate, the media  
776 was replaced and maintained with neurobasal media supplemented with B-27 (cat no. 17504-044,  
777 Invitrogen, Carlsbad CA), 1% Penicillin/Streptomycin, and 1% GlutaMAX Supplement (cat no.  
778 35050-079, Thermo Fisher Scientific, Waltham MA).

### 779 **Etoposide Treatment**

780 Primary cortical neuron cultures (DIV11-13) were treated with 1, 5, 10, 25, or 50uM etoposide  
781 prepared from 20mM stock (cat no. E1383-250MG, Sigma, St. Louis MO). Cultures were treated  
782 for either 3 or 6 hours before collection for downstream experiments. We used two SASP  
783 cytokines, *Ccl2* and *Cxcl10* (found significantly upregulated in Stage 2 neurons) as biomarkers for  
784 activation of immune signaling. Quantitative reverse transcription PCR (RT-qPCR) was used to  
785 measure gene expression. A six-hour 50 uM etoposide treatment resulted in a robust induction of  
786 compared to other time points and drug concentrations. We also observed that a 50uM etoposide  
787 treatment resulted in a marked increase in  $\gamma$ H2AX nuclear intensity compared to control cultures  
788 (Figure 2a).

### 789 **NFkB Activation Inhibitor**

790 Primary neuron cultures were treated with 10uM NF-kappaB Activation Inhibitor VI,  
791 benzothiole compound from Abcam (cat no. ab145954). Cultures were pre-treated for at least  
792 30 minutes before ETP exposure.

### 793 **RNA Scope In-Situ Hybridization**

794 Fluorescent in-situ hybridization was performed using the RNA Scope® Multiplex Fluorescent  
795 Reagent Kit v2 according to manufacturer's instructions (cat no. 323100, Advanced Cell  
796 Diagnostics, Newark CA). Probes targeting murine *Ccl2* (cat no. 311791) and *Cxcl10* (cat no.  
797 408921) were purchased from Advanced Cell Diagnostics. Following the RNA Scope protocol,  
798 slices were stained for  $\gamma$ H2AX (cat no. 05-636, EMD Millipore, Burlington MA). Samples were  
799 imaged with a Zeiss LSM 710 confocal microscope at 40x objective. Images were analyzed with  
800 ImageJ.

### 801 **RNA Scope Analysis**

802 ImageJ version 2.1.0 thresholding was used to identify  $\gamma$ H2AX-positive nuclei and generate ROIs.  
803 Process -> "Find Maxima" was used to count mRNA puncta within ROIs. Prominence >100.00  
804 with "Strict" setting. The number of  $\gamma$ H2AX-positive nuclei with  $2 \leq$  maxima were quantified, as  
805 well as the number of maxima per  $\gamma$ H2AX-positive nucleus.  $\gamma$ H2AX-negative nuclei were  
806 identified by thresholding for individual nuclei using the DAPI channel, then excluding ROIs that  
807 overlapped with  $\gamma$ H2AX-positive ROIs. Individual nuclei were identified following the Nuclei



808 Watershed Separation process described on the ImageJ website:  
809 [https://imagej.net/Nuclei\\_Watershed\\_Separation](https://imagej.net/Nuclei_Watershed_Separation)

## 810 **Brain tissue samples**

### 811 **MADRC brain tissue samples**

812 Fresh frozen postmortem brain samples were generously provided by the Massachusetts  
813 Alzheimer's Disease Research Center. These samples were used for bulk RNA-sequencing.  
814 Individuals were selected based on clinical diagnosis and Braak score. The three samples labeled  
815 as AD all had a clinical diagnosis of AD, and a Braak score of VI. The three samples labeled as  
816 non-AD did not have a clinical diagnosis of AD, and had Braak scores of I, II and II. Sample  
817 metadata is available in Supplementary Table 3.

### 818 **ROSMAP brain tissue samples**

819 Fixed frozen postmortem brain samples were chosen from the Religious Orders Study and Memory  
820 and Aging Project cohort (ROSMAP). ROSMAP is a longitudinal cohort study of ageing and  
821 dementia in elderly nuns, brothers and priests. Sample metadata is available in Supplementary  
822 Table 4. In-depth description of metadata variables are available at the Rush Alzheimer's Disease  
823 Center (RADC) website: <https://www.radc.rush.edu/docs/var/variables.htm>.

### 824 **P65 knock-down**

825 Custom p65 and scramble shRNA oligos cloned into an AAV backbone (pAV-U6-RFP) were  
826 purchased from ViGene Biosciences (Rockville, MD). P65 shRNA sequences were:

- 827 1. GATCCGGCAGGCTATCAGTCAGCGCATTGTGCTTATG  
828 CGCTGACTGATAGCCTGCTTTTTA
- 829 2. GATCCGCGGATTGAGGAGAAACGTAAATGTGCTTTTTA  
830 CGTTTCTCCTCAATCCGTTTTTA
- 831 3. GATCCGCACCATCAACTATGATGAGTTTGTGCTTAACT  
832 CATCATAGTTGATGGTGTTTTTA
- 833 4. GATCCGCCTGAGGCTATAACTCGCCTATGTGCTTTAGG  
834 CGAGTTATAGCCTCAGGTTTTTA
- 835 5. shRNA scramble: GATCCGCAACAAGATGAAGAGCACCAACTCGAGTTGG  
836 TGCTCTTCATCTTGTTGTTTTTA

837 P65 knockdown was confirmed via RT-qPCR in-house. PHP.eB AAV was generated by Janelia  
838 Viral Services. PHP.eB AAV shRNA or PBS was delivered retro-orbitally to anesthetized CK-p25  
839 mice,  $2 \times 10^{11}$ . Two weeks after injection, mice were induced by removing doxycycline diet.  
840 Following induction, mice were transcardially perfused with ice-cold PBS. One hemisphere was  
841 drop-fixed overnight in 4% paraformaldehyde/PBS at 4°C for immunostaining. The other  
842 hemisphere was flash-frozen in liquid nitrogen and stored at -80°C for RNA sequencing. 5  
843 Scramble and 5 p65 knock-down CK-p25 mice were used for RFP-positive  $\gamma$ H2AX-positive RT-

844 qPCR. A separate cohort of 7 CK, 5 Scramble, and 6 p65kd CK-p25 mice were used for PU.1-  
845 positive RNA-sequencing, and Iba1 and GFAP imaging analyses.

#### 846 **CK-p25 mice**

847 CK-p25 double transgenic mice were raised and maintained on a doxycycline diet. All mice were  
848 induced by removing doxycycline from their diet to drive the expression of p25-GFP in forebrain  
849 excitatory neurons. All mice were induced at 3-4 months old.

#### 850 **Conditioned media and Immunodepletion**

851 Following etoposide treatment, cultures were washed once with PBS. Cultures then recovered in  
852 fresh media for 24 hours. Media was collected and spun at 2,000g for 10 minutes to remove cellular  
853 debris. Media was stored at -80°C for future experiments. Conditioned media from etoposide-  
854 treated neurons were incubated with IgG, Ccl2, or Cxcl10 antibodies (all 40ug/mL) for 4 hours at  
855 4°C. Dynabeads™ Protein G were added to pull down the antibody complex.

#### 856 **Organotypic Brain Slice Culture**

857 8 through 12 week-old Cx3cr1-GFP male mice were anesthetized with isoflurane and  
858 transcardially-perfused, dissected, and sliced in ice-cold NMDG-cutting solution containing (in  
859 mM): 2.5 KCl, 0.5 CaCl<sub>2</sub>, 10 MgSO<sub>4</sub>, 1.25 NaH<sub>2</sub>PO<sub>4</sub>, 20 HEPES, 2 Thiourea, 5 sodium  
860 ascorbate, 3 sodium pyruvate, 92 NMDG, 30 NaHCO<sub>3</sub>, 25 D-Glucose, pH 7.3 – 7.4 with HCl. The  
861 slicing chamber was bubbled with 95% O<sub>2</sub>/5%CO<sub>2</sub>, and coronal slices were cut at 250 μm  
862 thickness using a vibratome (Leica, VT1000s). After the last slice was collected, slices were  
863 transferred to a well-plate containing fresh aCSF and placed in an incubator set at 37°C and 95%  
864 O<sub>2</sub>/5% CO<sub>2</sub> for 30 minutes. The aCSF solution contained (in mM): 125 NaCl, 2.5 KCl, 1.2  
865 NaH<sub>2</sub>PO<sub>4</sub>, 1.2 MgCl<sub>2</sub>, 2.4 CaCl<sub>2</sub>, 26 NaHCO<sub>3</sub>, 11 D-Glucose. Afterward, 100% of aCSF was  
866 removed and a 1:1 mixture of fresh aCSF and conditioned media was added to the slices and placed  
867 back into the incubator for 6 hours. At the completion of the experiment, slices were fixed  
868 overnight at 4°C with 4% paraformaldehyde. Slices were then incubated in 30% glucose overnight  
869 at 4°C. Slices were sub-sectioned into 25um slices using a cryostat, then cover-slipped for imaging.

#### 870 **ELISA**

871 The Mouse MCP1 ELISA Kit and Mouse IP-10 ELISA Kit from Abcam (cat no. ab208979 and  
872 ab214563 respectively) were used to quantify Ccl2 and Cxcl10 in conditioned media from primary  
873 neurons. Assays were quantified on a plate reader and protein concentration was calculated  
874 according to manual instructions.

#### 875 **Microglia morphological analysis**

876 Microglia morphology from CK-p25 and acute slice cultures was analyzed according to the  
877 protocol described in Young and Morrison, 2018 with minor alterations<sup>79</sup>. Gray Scale Attribute

878 Filtering (default settings, connectivity: 8) from the MorphoLibJ plug-in version 1.4.1 was used to  
879 reduce background noise when thresholding images for skeleton analysis. Following skeleton  
880 analysis, Morphological Filters (Operation: Opening, Element: Octagon, Radius (in pixels): 2)  
881 from MorphoLibJ was used to quantify soma area. This analysis was performed for both Iba1 and  
882 Cx3cr1-GFP imaging experiments.

883 **References**

- 884 1. Madabhushi, R., Pan, L. & Tsai, L.-H. DNA Damage and Its Links to Neurodegeneration. *Neuron* **83**,  
885 266–282 (2014).
- 886 2. Martin, L. J. DNA Damage and Repair: Relevance to Mechanisms of Neurodegeneration. *J.*  
887 *Neuropathol. Exp. Neurol.* **67**, 377–387 (2008).
- 888 3. Hoeijmakers, J. H. J. DNA Damage, Aging, and Cancer. *N. Engl. J. Med.* **361**, 1475–1485 (2009).
- 889 4. Lu, T. *et al.* Gene regulation and DNA damage in the ageing human brain. *Nature* **429**, 883–891  
890 (2004).
- 891 5. Adamec, E., Vonsattel, J. P. & Nixon, R. A. DNA strand breaks in Alzheimer’s disease. *Brain Res.*  
892 **849**, 67–77 (1999).
- 893 6. Lovell, M. A. & Markesbery, W. R. Oxidative DNA damage in mild cognitive impairment and late-  
894 stage Alzheimer’s disease. *Nucleic Acids Res.* **35**, 7497–7504 (2007).
- 895 7. Jacobsen, E., Beach, T., Shen, Y., Li, R. & Chang, Y. Deficiency of the Mre11 DNA repair complex  
896 in Alzheimer’s disease brains. *Mol. Brain Res.* **128**, 1–7 (2004).
- 897 8. Shanbhag, N. M. *et al.* Early neuronal accumulation of DNA double strand breaks in Alzheimer’s  
898 disease. *Acta Neuropathol. Commun.* **7**, 77 (2019).
- 899 9. Kim, D. *et al.* Dereglulation of HDAC1 by p25/Cdk5 in Neurotoxicity. *Neuron* **60**, 803–817 (2008).
- 900 10. Sykora, P. *et al.* DNA polymerase  $\beta$  deficiency leads to neurodegeneration and exacerbates  
901 Alzheimer disease phenotypes. *Nucleic Acids Res.* **43**, 943–959 (2015).
- 902 11. Dobbin, M. M. *et al.* SIRT1 collaborates with ATM and HDAC1 to maintain genomic stability in  
903 neurons. *Nat. Neurosci.* **16**, 1008–1015 (2013).

- 904 12. Suberbielle, E. *et al.* DNA repair factor BRCA1 depletion occurs in Alzheimer brains and impairs  
905 cognitive function in mice. *Nat. Commun.* **6**, 8897 (2015).
- 906 13. Suberbielle, E. *et al.* Physiologic brain activity causes DNA double-strand breaks in neurons, with  
907 exacerbation by amyloid- $\beta$ . *Nat. Neurosci.* **16**, 613–621 (2013).
- 908 14. Hayano, M. *et al.* *DNA Break-Induced Epigenetic Drift as a Cause of Mammalian Aging.*  
909 <https://papers.ssrn.com/abstract=3466338> (2019) doi:10.2139/ssrn.3466338.
- 910 15. Wu, W. *et al.* Neuronal enhancers are hotspots for DNA single-strand break repair. *Nature* **593**, 440–  
911 444 (2021).
- 912 16. Reid, D. A. *et al.* Incorporation of a nucleoside analog maps genome repair sites in postmitotic  
913 human neurons. *Science* **372**, 91–94 (2021).
- 914 17. Härtlova, A. *et al.* DNA Damage Primes the Type I Interferon System via the Cytosolic DNA Sensor  
915 STING to Promote Anti-Microbial Innate Immunity. *Immunity* **42**, 332–343 (2015).
- 916 18. Dou, Z. *et al.* Cytoplasmic chromatin triggers inflammation in senescence and cancer. *Nature* **550**,  
917 402–406 (2017).
- 918 19. Janssens, S. & Tschopp, J. Signals from within: the DNA-damage-induced NF- $\kappa$ B response. *Cell*  
919 *Death Differ.* **13**, 773–784 (2006).
- 920 20. McCool, K. W. & Miyamoto, S. DNA damage-dependent NF- $\kappa$ B activation: NEMO turns nuclear  
921 signaling inside out. *Immunol. Rev.* **246**, 311–326 (2012).
- 922 21. Rodier, F. *et al.* Persistent DNA damage signalling triggers senescence-associated inflammatory  
923 cytokine secretion. *Nat. Cell Biol.* **11**, 973–979 (2009).
- 924 22. Chien, Y. *et al.* Control of the senescence-associated secretory phenotype by NF- $\kappa$ B promotes  
925 senescence and enhances chemosensitivity. *Genes Dev.* **25**, 2125–2136 (2011).

- 926 23. Klein, R. S. *et al.* Neuronal CXCL10 Directs CD8<sup>+</sup> T-Cell Recruitment and Control of West Nile  
927 Virus Encephalitis. *J. Virol.* **79**, 11457–11466 (2005).
- 928 24. Préhaud, C., Mégret, F., Lafage, M. & Lafon, M. Virus Infection Switches TLR-3-Positive Human  
929 Neurons To Become Strong Producers of Beta Interferon. *J. Virol.* **79**, 12893–12904 (2005).
- 930 25. Cruz, J. C., Tseng, H.-C., Goldman, J. A., Shih, H. & Tsai, L.-H. Aberrant Cdk5 Activation by p25  
931 Triggers Pathological Events Leading to Neurodegeneration and Neurofibrillary Tangles. *Neuron* **40**,  
932 471–483 (2003).
- 933 26. Mathys, H. *et al.* Temporal Tracking of Microglia Activation in Neurodegeneration at Single-Cell  
934 Resolution. *Cell Rep.* **21**, 366–380 (2017).
- 935 27. Cruz, J. C. *et al.* p25/Cyclin-Dependent Kinase 5 Induces Production and Intraneuronal  
936 Accumulation of Amyloid beta In Vivo. *J. Neurosci.* **26**, 10536–10541 (2006).
- 937 28. Fischer, A., Sananbenesi, F., Pang, P. T., Lu, B. & Tsai, L.-H. Opposing Roles of Transient and  
938 Prolonged Expression of p25 in Synaptic Plasticity and Hippocampus-Dependent Memory. *Neuron*  
939 **48**, 825–838 (2005).
- 940 29. Gjoneska, E. *et al.* Conserved epigenomic signals in mice and humans reveal immune basis of  
941 Alzheimer’s disease. *Nature* **518**, 365–369 (2015).
- 942 30. Mah, L.-J., El-Osta, A. & Karagiannis, T. C.  $\gamma$ H2AX: a sensitive molecular marker of DNA damage  
943 and repair. *Leukemia* **24**, 679–686 (2010).
- 944 31. Caldwell, A. B. *et al.* Dedifferentiation and neuronal repression define familial Alzheimer’s disease.  
945 *Sci. Adv.* **6**, eaba5933 (2020).
- 946 32. Mertens, J. *et al.* Age-dependent instability of mature neuronal fate in induced neurons from  
947 Alzheimer’s patients. *Cell Stem Cell* (2021) doi:10.1016/j.stem.2021.04.004.

- 948 33. Yousef, A. *et al.* Neuron loss and degeneration in the progression of TDP-43 in frontotemporal lobar  
949 degeneration. *Acta Neuropathol. Commun.* **5**, 68 (2017).
- 950 34. Ünal-Çevik, I., Kılınç, M., Gürsoy-Özdemir, Y., Gurer, G. & Dalkara, T. Loss of NeuN  
951 immunoreactivity after cerebral ischemia does not indicate neuronal cell loss: a cautionary note.  
952 *Brain Res.* **1015**, 169–174 (2004).
- 953 35. McPhail, L. T., McBride, C. B., McGraw, J., Steeves, J. D. & Tetzlaff, W. Axotomy abolishes NeuN  
954 expression in facial but not rubrospinal neurons. *Exp. Neurol.* **185**, 182–190 (2004).
- 955 36. Wu, K.-L. *et al.* Loss of Neuronal Protein Expression in Mouse Hippocampus After Irradiation. *J.*  
956 *Neuropathol. Exp. Neurol.* **69**, 272–280 (2010).
- 957 37. Collombet, J.-M. *et al.* Early reduction of NeuN antigenicity induced by soman poisoning in mice can  
958 be used to predict delayed neuronal degeneration in the hippocampus. *Neurosci. Lett.* **398**, 337–342  
959 (2006).
- 960 38. Subramanian, A. *et al.* Gene set enrichment analysis: A knowledge-based approach for interpreting  
961 genome-wide expression profiles. *Proc. Natl. Acad. Sci.* **102**, 15545–15550 (2005).
- 962 39. Yang, Y., Geldmacher, D. S. & Herrup, K. DNA Replication Precedes Neuronal Cell Death in  
963 Alzheimer’s Disease. *J. Neurosci.* **21**, 2661–2668 (2001).
- 964 40. Busser, J., Geldmacher, D. S. & Herrup, K. Ectopic Cell Cycle Proteins Predict the Sites of Neuronal  
965 Cell Death in Alzheimer’s Disease Brain. *J. Neurosci.* **18**, 2801–2807 (1998).
- 966 41. Sokolova, A. *et al.* Monocyte Chemoattractant Protein-1 Plays a Dominant Role in the Chronic  
967 Inflammation Observed in Alzheimer’s Disease. *Brain Pathol.* **19**, 392–398 (2009).
- 968 42. El Khoury, J. *et al.* Ccr2 deficiency impairs microglial accumulation and accelerates progression of  
969 Alzheimer-like disease. *Nat. Med.* **13**, 432–438 (2007).

- 970 43. Chai, Q., She, R., Huang, Y. & Fu, Z. F. Expression of Neuronal CXCL10 Induced by Rabies Virus  
971 Infection Initiates Infiltration of Inflammatory Cells, Production of Chemokines and Cytokines, and  
972 Enhancement of Blood-Brain Barrier Permeability. *J. Virol.* **89**, 870–876 (2014).
- 973 44. Conductier, G., Blondeau, N., Guyon, A., Nahon, J.-L. & Rovère, C. The role of monocyte  
974 chemoattractant protein MCP1/CCL2 in neuroinflammatory diseases. *J. Neuroimmunol.* **224**, 93–100  
975 (2010).
- 976 45. Chen, E. Y. *et al.* Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool.  
977 *BMC Bioinformatics* **14**, 128 (2013).
- 978 46. Kuleshov, M. V. *et al.* Enrichr: a comprehensive gene set enrichment analysis web server 2016  
979 update. *Nucleic Acids Res.* **44**, W90-97 (2016).
- 980 47. Xie, Z. *et al.* Gene Set Knowledge Discovery with Enrichr. *Curr. Protoc.* **1**, e90 (2021).
- 981 48. Trapnell, C. *et al.* The dynamics and regulators of cell fate decisions are revealed by pseudotemporal  
982 ordering of single cells. *Nat. Biotechnol.* **32**, 381–386 (2014).
- 983 49. Qiu, X. *et al.* Reversed graph embedding resolves complex single-cell trajectories. *Nat. Methods* **14**,  
984 979–982 (2017).
- 985 50. Cao, J. *et al.* The single-cell transcriptional landscape of mammalian organogenesis. *Nature* **566**,  
986 496–502 (2019).
- 987 51. Wang, C. *et al.* Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is  
988 ameliorated by a small-molecule structure corrector. *Nat. Med.* **24**, 647–657 (2018).
- 989 52. Dunphy, G. *et al.* Non-canonical Activation of the DNA Sensing Adaptor STING by ATM and IFI16  
990 Mediates NF- $\kappa$ B Signaling after Nuclear DNA Damage. *Mol. Cell* **71**, 745-760.e5 (2018).



- 991 53. Mathys, H. *et al.* Single-cell transcriptomic analysis of Alzheimer’s disease. *Nature* **570**, 332–337  
992 (2019).
- 993 54. Variable Details | RADc.  
994 [https://www.radc.rush.edu/docs/var/detail.htm?category=Pathology&subcategory=Alzheimer%27s+d](https://www.radc.rush.edu/docs/var/detail.htm?category=Pathology&subcategory=Alzheimer%27s+disease&variable=gpath)  
995 [isease&variable=gpath](https://www.radc.rush.edu/docs/var/detail.htm?category=Pathology&subcategory=Alzheimer%27s+disease&variable=gpath).
- 996 55. Chan, K. Y. *et al.* Engineered AAVs for efficient noninvasive gene delivery to the central and  
997 peripheral nervous systems. *Nat. Neurosci.* **20**, 1172–1179 (2017).
- 998 56. Chang, A. L. *et al.* CCL2 Produced by the Glioma Microenvironment Is Essential for the Recruitment  
999 of Regulatory T Cells and Myeloid-Derived Suppressor Cells. *Cancer Res.* **76**, 5671–5682 (2016).
- 1000 57. Semple, B. D., Bye, N., Rancan, M., Ziebell, J. M. & Morganti-Kossmann, M. C. Role of CCL2  
1001 (MCP-1) in traumatic brain injury (TBI): evidence from severe TBI patients and CCL2<sup>-/-</sup> mice. *J.*  
1002 *Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab.* **30**, 769–782 (2010).
- 1003 58. Galimberti, D. *et al.* Serum MCP-1 levels are increased in mild cognitive impairment and mild  
1004 Alzheimer’s disease. *Neurobiol. Aging* **27**, 1763–1768 (2006).
- 1005 59. Bradburn, S. *et al.* Dysregulation of C-X-C motif ligand 10 during aging and association with  
1006 cognitive performance. *Neurobiol. Aging* **63**, 54–64 (2018).
- 1007 60. Zhang, B. *et al.* Integrated Systems Approach Identifies Genetic Nodes and Networks in Late-Onset  
1008 Alzheimer’s Disease. *Cell* **153**, 707–720 (2013).
- 1009 61. Keren-Shaul, H. *et al.* A Unique Microglia Type Associated with Restricting Development of  
1010 Alzheimer’s Disease. *Cell* **169**, 1276-1290.e17 (2017).

- 1011 62. Alzheimer Disease Genetics Consortium (ADGC), *et al.* Genetic meta-analysis of diagnosed  
1012 Alzheimer's disease identifies new risk loci and implicates A $\beta$ , tau, immunity and lipid processing.  
1013 *Nat. Genet.* **51**, 414–430 (2019).
- 1014 63. Nott, A. *et al.* Brain cell type-specific enhancer–promoter interactome maps and disease - risk  
1015 association. *Science* **366**, 1134–1139 (2019).
- 1016 64. Ramamurthy, E. *et al.* Cell type-specific histone acetylation profiling of Alzheimer's Disease subjects  
1017 and integration with genetics. 2020.03.26.010330  
1018 <https://www.biorxiv.org/content/10.1101/2020.03.26.010330v1> (2020)  
1019 doi:10.1101/2020.03.26.010330.
- 1020 65. Shi, Y. *et al.* Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model. *J.*  
1021 *Exp. Med.* **216**, 2546–2561 (2019).
- 1022 66. Spangenberg, E. *et al.* Sustained microglial depletion with CSF1R inhibitor impairs parenchymal  
1023 plaque development in an Alzheimer's disease model. *Nat. Commun.* **10**, 3758 (2019).
- 1024 67. Spangenberg, E. E. *et al.* Eliminating microglia in Alzheimer's mice prevents neuronal loss without  
1025 modulating amyloid- $\beta$  pathology. *Brain* **139**, 1265–1281 (2016).
- 1026 68. Song, W. M. & Colonna, M. The identity and function of microglia in neurodegeneration. *Nat.*  
1027 *Immunol.* **19**, 1048–1058 (2018).
- 1028 69. Simon, M. *et al.* LINE1 Derepression in Aged Wild-Type and SIRT6-Deficient Mice Drives  
1029 Inflammation. *Cell Metab.* **29**, 871-885.e5 (2019).
- 1030 70. Lee, H. *et al.* Cell Type-Specific Transcriptomics Reveals that Mutant Huntingtin Leads to  
1031 Mitochondrial RNA Release and Neuronal Innate Immune Activation. *Neuron* **107**, 891-908.e8  
1032 (2020).

- 1033 71. Wyss-Coray, T. & Rogers, J. Inflammation in Alzheimer Disease—A Brief Review of the Basic  
1034 Science and Clinical Literature. *Cold Spring Harb. Perspect. Med.* **2**, (2012).
- 1035 72. Kaltschmidt, B. *et al.* NF-kappaB regulates spatial memory formation and synaptic plasticity through  
1036 protein kinase A/CREB signaling. *Mol. Cell. Biol.* **26**, 2936–2946 (2006).
- 1037 73. Fridmacher, V. *et al.* Forebrain-Specific Neuronal Inhibition of Nuclear Factor- $\kappa$ B Activity Leads to  
1038 Loss of Neuroprotection. *J. Neurosci.* **23**, 9403–9408 (2003).
- 1039 74. Mahad, D. *et al.* Modulating CCR2 and CCL2 at the blood–brain barrier: relevance for multiple  
1040 sclerosis pathogenesis. *Brain* **129**, 212–223 (2006).
- 1041 75. Dimitrijevic, O. B., Stamatovic, S. M., Keep, R. F. & Andjelkovic, A. V. Effects of the Chemokine  
1042 CCL2 on Blood–Brain Barrier Permeability during Ischemia–Reperfusion Injury. *J. Cereb. Blood*  
1043 *Flow Metab.* **26**, 797–810 (2006).
- 1044 76. Naert, G. & Rivest, S. CC Chemokine Receptor 2 Deficiency Aggravates Cognitive Impairments and  
1045 Amyloid Pathology in a Transgenic Mouse Model of Alzheimer’s Disease. *J. Neurosci.* **31**, 6208–  
1046 6220 (2011).
- 1047 77. Yamamoto, M. *et al.* Overexpression of Monocyte Chemotactic Protein-1/CCL2 in  $\beta$ -Amyloid  
1048 Precursor Protein Transgenic Mice Show Accelerated Diffuse  $\beta$ -Amyloid Deposition. *Am. J. Pathol.*  
1049 **166**, 1475–1485 (2005).
- 1050 78. Krauthausen, M. *et al.* CXCR3 promotes plaque formation and behavioral deficits in an Alzheimer’s  
1051 disease model. *J. Clin. Invest.* **125**, 365–378 (2015).
- 1052 79. Young, K. & Morrison, H. Quantifying Microglia Morphology from Photomicrographs of  
1053 Immunohistochemistry Prepared Tissue Using ImageJ. *J. Vis. Exp.* 57648 (2018) doi:10.3791/57648.
- 1054

1055 [Methods References](#)

- 1056 1. Kolberg, Liis, Uku Raudvere, Ivan Kuzmin, Jaak Vilo, and Hedi Peterson. “Gprofiler2 -- an R  
1057 Package for Gene List Functional Enrichment Analysis and Namespace Conversion Toolset  
1058 g:Profiler.” *F1000Research* 9 (November 17, 2020): 709.  
1059 <https://doi.org/10.12688/f1000research.24956.2>.
- 1060 2. Liao, Yang, Gordon K. Smyth, and Wei Shi. “The R Package Rsubread Is Easier, Faster,  
1061 Cheaper and Better for Alignment and Quantification of RNA Sequencing Reads.” *Nucleic  
1062 Acids Research* 47, no. 8 (May 7, 2019): e47. <https://doi.org/10.1093/nar/gkz114>.
- 1063 3. Mohammadi, Shahin, Jose Davila-Velderrain, and Manolis Kellis. “A Multiresolution  
1064 Framework to Characterize Single-Cell State Landscapes.” *Nature Communications* 11, no. 1  
1065 (October 26, 2020): 5399. <https://doi.org/10.1038/s41467-020-18416-6>.
- 1066 4. Robinson, Mark D., Davis J. McCarthy, and Gordon K. Smyth. “EdgeR: A Bioconductor  
1067 Package for Differential Expression Analysis of Digital Gene Expression Data.”  
1068 *Bioinformatics (Oxford, England)* 26, no. 1 (January 1, 2010): 139–40.  
1069 <https://doi.org/10.1093/bioinformatics/btp616>.
- 1070 5. Bennett, David A., Aron S. Buchman, Patricia A. Boyle, Lisa L. Barnes, Robert S. Wilson,  
1071 and Julie A. Schneider. “Religious Orders Study and Rush Memory and Aging Project.”  
1072 *Journal of Alzheimer’s Disease: JAD* 64, no. s1 (2018): S161–89.  
1073 <https://doi.org/10.3233/JAD-179939>.
- 1074 6. Swiech, Lukasz, Matthias Heidenreich, Abhishek Banerjee, Naomi Habib, Yinqing Li, John  
1075 Trombetta, Mriganka Sur, and Feng Zhang. “In Vivo Interrogation of Gene Function in the  
1076 Mammalian Brain Using CRISPR-Cas9.” *Nature Biotechnology* 33, no. 1 (January 2015):  
1077 102–6. <https://doi.org/10.1038/nbt.3055>.

- 1078 7. Dobin, Alexander, Carrie A. Davis, Felix Schlesinger, Jorg Drenkow, Chris Zaleski, Sonali  
1079 Jha, Philippe Batut, Mark Chaisson, and Thomas R. Gingeras. “STAR: Ultrafast Universal  
1080 RNA-Seq Aligner.” *Bioinformatics (Oxford, England)* 29, no. 1 (January 1, 2013): 15–21.  
1081 <https://doi.org/10.1093/bioinformatics/bts635>.
- 1082 8. Anders, Simon, Paul Theodor Pyl, and Wolfgang Huber. “HTSeq--a Python Framework to  
1083 Work with High-Throughput Sequencing Data.” *Bioinformatics (Oxford, England)* 31, no. 2  
1084 (January 15, 2015): 166–69. <https://doi.org/10.1093/bioinformatics/btu638>.
- 1085 9. Wolf, F. Alexander, Philipp Angerer, and Fabian J. Theis. “SCANPY: Large-Scale Single-  
1086 Cell Gene Expression Data Analysis.” *Genome Biology* 19, no. 1 (February 6, 2018): 15.  
1087 <https://doi.org/10.1186/s13059-017-1382-0>.
- 1088 10. De Jager, Philip L., Yiyi Ma, Cristin McCabe, Jishu Xu, Badri N. Vardarajan, Daniel Felsky,  
1089 Hans-Ulrich Klein, et al. “A Multi-Omic Atlas of the Human Frontal Cortex for Aging and  
1090 Alzheimer’s Disease Research.” *Scientific Data* 5, no. 1 (August 7, 2018): 180142.  
1091 <https://doi.org/10.1038/sdata.2018.142>.
- 1092 11. Storey, John D., Andrew J. Bass, Alan Dabney, David Robinson, and Gregory Warnes.  
1093 *Qvalue: Q-Value Estimation for False Discovery Rate Control* (version 2.22.0). Bioconductor  
1094 version: Release (3.12), 2021. <https://doi.org/10.18129/B9.bioc.qvalue>.
- 1095 12. Raudvere, Uku, Liis Kolberg, Ivan Kuzmin, Tambet Arak, Priit Adler, Hedi Peterson, and  
1096 Jaak Vilo. “G:Profiler: A Web Server for Functional Enrichment Analysis and Conversions of  
1097 Gene Lists (2019 Update).” *Nucleic Acids Research* 47, no. W1 (July 2, 2019): W191–98.  
1098 <https://doi.org/10.1093/nar/gkz369>.

- 1099 13. Jassal, Bijay, Lisa Matthews, Guilherme Viteri, Chuqiao Gong, Pascual Lorente, Antonio  
1100 Fabregat, Konstantinos Sidiropoulos, et al. “The Reactome Pathway Knowledgebase.” *Nucleic*  
1101 *Acids Research* 48, no. D1 (January 8, 2020): D498–503. <https://doi.org/10.1093/nar/gkz1031>.  
1102 14. Ligtenberg, W. “Reactome.Db: A Set of Annotation Maps for Reactome Assembled Using  
1103 Data from Reactome.” Bioconductor, 2019. <http://bioconductor.org/packages/reactome.db/>.  
1104 15. Mathys, Hansruedi, Jose Davila-Velderrain, Zhuyu Peng, Fan Gao, Shahin Mohammadi,  
1105 Jennie Z. Young, Madhvi Menon, et al. “Single-Cell Transcriptomic Analysis of Alzheimer’s  
1106 Disease.” *Nature* 570, no. 7761 (June 2019): 332–37. [https://doi.org/10.1038/s41586-019-](https://doi.org/10.1038/s41586-019-1195-2)  
1107 [1195-2](https://doi.org/10.1038/s41586-019-1195-2).

## 1108 **Acknowledgements**

1109 We thank M. Saturno-Condon, M. Jennings, M. Griffin, and G. Paradis from the Swanson  
1110 Biotechnology Center Flow Cytometry Facility for assistance with FANS. We thank S. Levine, N.  
1111 Kamelamela, and A. Hendricks from the MIT BioMicro Center for assistance with RNA  
1112 sequencing and library preparation. We thank K. Cormier from the MIT Hope Babetter Tang  
1113 (1983) Histology Core Facility and J. Khun from the MIT Microscopy Core Facility for assistance  
1114 with Visium Spatial Gene Expression sample preparation. This work was supported by NIH grants  
1115 AG054012, AG058002, AG062377, NS110453, NS115064, AG067151, AG062335, MH109978,  
1116 MH119509, and HG008155 (to M.K. and L.H.T), 5 R01 NS102730-03 (to L.H.T), and CureAlz  
1117 CIRCUITS, and the Glenn Foundation for Medical Research. This work was also supported by  
1118 NIH fellowship 5F31NS113464-02 to G.W. V.D. is supported by the AARF-19-618751 grant from  
1119 the Alzheimer’s Association. M.B.V. is supported by HHMI Hanna H. Gray Fellowship. C.A.B.  
1120 is supported by the NIH training grant GM087237.

## 1121 **Figure Legends**

### 1122 **Figure 1. Neurons marked by DNA DSBs activate inflammatory signaling at early stages of** 1123 **neurodegeneration.**

1124 **a.** Flow cytometry dot plots of  $\gamma$ H2AX<sup>+</sup> nuclei from CK and CK-p25 cortex.  $\gamma$ H2AX<sup>+</sup> are  
1125 highlighted in turquoise, and percent total population is indicated above the gating box.

1126 **b.** CK-p25 mice were taken off dox for 1 through 6 weeks, then cortical nuclei were extracted  
1127 and stained for  $\gamma$ H2AX. Each datapoint represents percent  $\gamma$ H2AX<sup>+</sup> nuclei from one mouse  
1128 cortex.

1129 **c.** RNA seq workflow for the gated populations. Bulk RNA-seq: Cortices were extracted from  
1130 CK and CK-p25 mice (n=2 per genotype for bulk RNA-seq, 2-week timepoint only). Tissue was  
1131 homogenized, then nuclei were extracted and stained for NeuN and  $\gamma$ H2AX. 50,000 nuclei were  
1132 sorted from each gated population. snRNA-seq: Cortices were extracted from CK and CK-p25  
1133 mice (n=3 per genotype $\times$ timepoint for SMART-seq, 1-week and 2-week timepoints). Tissue was  
1134 homogenized, then nuclei were extracted and stained for NeuN and  $\gamma$ H2AX. 48 nuclei were  
1135 sorted for each gated CK-p25 population per mouse, and 32 nuclei were sorted for each gated  
1136 CK population per mouse.

1137 **d.** Differential gene ontology terms from gene set enrichment analysis (GSEA) of bulk RNAseq  
1138 data. Left column depicts GSEA results from Stage 1 vs. CK-p25 Baseline contrast. Right  
1139 column depicts GSEA results from Stage 2 vs. CK-p25 Baseline contrast. Color indicates  
1140 normalized enrichment score (NES). Size indicates false discovery rate (FDR).

1141 **e.** Heatmap of differentially expressed genes belonging to inflammatory gene sets from bulk  
1142 RNA-seq data. Each column represents one mouse. Gene sets are organized by biological  
1143 function.

1144 **f.** (left): Representative images of Ccl2 RNAscope combined with  $\gamma$ H2AX immunofluorescent  
1145 staining. Imaging was performed on 1wk and 2wk CK-p25 cortex. (right): Quantification of  
1146 number of  $\gamma$ H2AX<sup>+</sup> and  $\gamma$ H2AX<sup>-</sup> cells with  $2 \leq$  Ccl2 puncta. Each datapoint represents average  
1147 %Ccl2-positive cells in one image from one mouse. 4-3 images were taken per mouse. (Ccl2  
1148 1wk n=4, Ccl2 2wk n=5)

1149 **g.** Representative image of p65 immunostaining in CK-p25 cortex at two-week timepoint. White  
1150 arrowheads indicate  $\gamma$ H2AX<sup>+</sup> nuclei with nuclear p65 immunoreactivity. Quantification of p65  
1151 mean intensity for  $\gamma$ H2AX<sup>+</sup> and  $\gamma$ H2AX<sup>-</sup> nuclei. Each data point represents the average p65  
1152 nuclear mean gray value of 20-60 nuclei from one mouse.

1153 **h.** UMAP of gated populations from CK and CK-p25 cortex at 1-week and 2-week timepoints.  
1154 Colors indicate cell type annotation.

1155 **i.** Marker gene expression for each cell type cluster. Columns represent 985 individual cells  
1156 ordered by cell type cluster.

1157 **j.** Trajectory analysis of Ex0,1,2,3, and Stage 2 neurons. Cells from each cluster (indicated by  
1158 color annotation) are ordered across pseudotime (indicated by color gradient).

1159 **k.** Trajectory analysis of Ex0,1,2,3, and Stage 2 neurons. Smoothed gene signature expression  
1160 across pseudotime. Stage 1=Significantly upregulated genes from Stage 1 vs. Baseline contrast.  
1161 Stage 2= Significantly upregulated genes from Stage 2 vs. Baseline contrast. Immune= Genes  
1162 belonging to immune gene ontologies that were significantly upregulated in Stage 2 neurons.  
1163  $p_{adj} < 0.05$ ,  $\text{Log}_2$  fold-change  $\geq 1.0$ .

1164 Error bars represent standard error of mean (S.E.M.); \*\*\*\* $P < 0.0001$ , \*\*\* $P < 0.001$ , \*\* $P < 0.01$ ,  
1165 \* $P < 0.05$ ; One-way ANOVA with Tukey's test for multiple comparisons (b,f). Two-way ANOVA  
1166 followed by Sidak's test for multiple comparisons (g). Data are pooled from 4 independent  
1167 experiments (b). Data are representative of two independent experiments (f,g).



1168 **Figure 2. Induction of DNA DSBs is sufficient to elicit immune pathway signaling in neuron**  
1169 **primary culture.**

1170 **a.** Top: Representative images of NeuN and  $\gamma$ H2AX immunostaining in ETP and vehicle-treated  
1171 primary cultures.  $\gamma$ H2AX immunoreactivity is quantified for each condition. Each data point  
1172 represents  $\gamma$ H2AX mean gray value for one nucleus in the representative image. Bottom:  
1173 Representative images of p65 immunostaining in ETP and vehicle-treated primary cultures. p65  
1174 immunoreactivity is quantified for each condition. Each data point represents p65 mean gray value  
1175 for one nucleus in the representative image.

1176 **b.** Schematic of etoposide (ETP) treatment. DIV13 neuron primary culture were treated with either  
1177 50uM ETP or vehicle control (DMSO) for 6 hours. mRNA was extracted from the cultures and  
1178 sequenced.

1179 **c.** Differential gene ontology terms identified through gene set enrichment analysis (GSEA) from  
1180 ETP vs. DMSO contrast.

1181 **d.** Heatmap of Stage 1 and Stage 2 signature enrichment (from bulk RNAseq) in DMSO and ETP-  
1182 treated neurons.

1183 **e.** Venn diagram of significantly upregulated protein-coding genes from ETP-treated neurons and  
1184 Stage 1 and Stage 2 gene signatures. Percentages are in reference to the total number of unique  
1185 genes from all three gene sets. Example genes are shown to the right. Genes overlapping in ETP  
1186 and Stage 2 are in turquoise. Genes overlapping in ETP, Stage 2, and Stage 1 are in magenta. The  
1187 area of the circles are in proportion to the size of the gene sets.

1188 **f.** Representative images of NeuN and  $\gamma$ H2AX immunostaining from 10 Gy and 0 Gy x-ray  
1189 irradiation treated primary neurons.

1190 **g.** qRT-PCR of Cdkn1a, Ccl2, and Cxcl10 in 10 Gy irradiated primary neurons. Each datapoint  
1191 represents one biological replicate.

1192 Error bars represent standard error of mean (S.E.M.); \*\*\*\*P<0.0001, \*\*\*P<0.001. Student's T-  
1193 test (a,g). Data are representative of 3 independent experiments (a). Data are representative of 2  
1194 independent experiments (g).

1195 **Figure 3. Inflammatory signaling in DSB-bearing neurons is positively correlated with**  
1196 **Alzheimer's disease pathology.**

1197 **a.** Schematic of the Stage 2 signature analysis in the snRNA-seq dataset from Mathys et al., 2019.

1198 **b.** Quantification of Stage 2 signature correlation with global pathology in celltype clusters from  
1199 Mathys et al., 2019. It was tested if stage 2 genes were significantly and positively correlated with  
1200 the global pathology metric for each major celltype. The  $-\log_{10}$  p-value for these tests are shown  
1201 in the histogram. The dashed line indicates a p-value of 0.01 after Bonferroni correction for  
1202 multiple testing. Excitatory neurons (Ex), Inhibitory neurons (In), Astrocytes (Ast),  
1203 Oligodendrocytes (Oli), Oligodendrocyte precursor cells (Opc), Microglia (Mic).

1204 **c.** Stage 2 signature genes ranked by their correlation with global pathology in excitatory neurons.  
1205 Stage 2 genes with positive correlation are shown with red circles.

1206 **d.** Gene ontology enrichment of Stage 2 signature genes positively correlated with global  
1207 pathology.

1208 **e.** Schematic of  $\gamma$ H2AX<sup>+</sup> nuclei sorting from AD and non-AD brain tissue.

1209 **f.** Heatmap of Stage 1 and Stage 2 signature enrichment in  $\gamma$ H2AX<sup>+</sup> and  $\gamma$ H2AX<sup>-</sup> human NeuN<sup>+</sup>  
1210 nuclei.

1211 **g-i.** Quantification of Stage 1 and Stage 2 signature enrichment in  $\gamma$ H2AX<sup>+</sup> and  $\gamma$ H2AX<sup>-</sup> human  
1212 NeuN<sup>+</sup> nuclei samples by FANS gate (g), and FANS gate and disease status (h,i).

1213 **j.** Representative image of  $\gamma$ H2AX, p65, and NeuN in the AD brain. Left: two NeuN-positive  
1214 nuclei are outlined (white dashed line). Right: magnification of the two outlined nuclei. Top  
1215 nucleus (A) represents low  $\gamma$ H2AX burden, bottom nucleus (B) represents high  $\gamma$ H2AX burden.

1216 **k.** Quantification of p65 nuclear enrichment in low and high  $\gamma$ H2AX-burdened neurons. Each dot  
1217 represents the average of 23-41 NeuN<sup>+</sup> nuclei per individual.

1218 Error bars represent standard error of mean (S.E.M.); \*\*\*\*P<0.0001, \*\*\*P<0.001, \*\*P<0.01,  
1219 \*P<0.05, ns not significant. T-test (k). Wilcoxon test (g-i).

1220 **Figure 4. Immune signaling in neurons recruits and activates microglia.**

1221 **a.** Schematic of spatial transcriptomics experiment. CK (n=3) and CK-p25 (n=4) were induced for  
1222 two weeks. Coronal brain sections were stained and imaged for  $\gamma$ H2AX, then sequenced.

1223 **b.** UMAP of capture areas from all samples. Leiden clusters are indicated by color and number.  
1224 Each dot represents one capture area.

1225 **c.** Leiden clusters superimposed onto a CK-p25 brain slice used for spatial transcriptomics.

1226 **d.** UMAP indicating the density of  $\gamma$ H2AX-positive capture areas.

1227 **e.**  $\gamma$ H2AX-positive capture areas identified in one CK-p25 brain slice.

1228 **f.** Spatial clusters,  $\gamma$ H2AX-positive capture areas, and reactive microglia signature gene expression  
1229 in one CK-p25 sample.

1230 **g.** Schematic of neuronal p65 knock-down experiment. CK-p25 mice receive retro-orbital  
1231 injections of scramble shRNA-RFP AAV or shp65-RFP AAV. CK mice received retro-orbital  
1232 injections of PBS. Mice were allowed to recover for two weeks before being taken off dox. Brains  
1233 were collected for subsequent analysis at the two week timepoint.

1234 **h.** qRT-PCR of immune genes in sorted  $\gamma$ H2AX+ nuclei.

1235 **i.** Representative images of Iba1 immunostaining in CK, Scramble, and p65kd cortex.

1236 **j.** Quantification of (left to right): Iba1+ soma area, number Iba1+ per image, average branch  
1237 length per Iba1+ cell, and number end-points per Iba1+ cell. Each data point represents one image.  
1238 Two images were taken per mouse.

1239 **k.** Heat map of differentially expressed genes from P65 vs. Scramble contrast. Each column  
1240 represents one mouse.

1241 **l.** Upregulated and downregulated gene ontology (biological pathway) terms identified through  
1242 gene set enrichment analysis (GSEA) from p65 kd vs. scramble contrast.

1243 **m.** Heatmap of significantly upregulated and downregulated genes in Pu.1+ nuclei from p65 kd  
1244 cortex compared to Pu.1+ nuclei from scramble cortex. Each row represents gene expression from  
1245 one mouse.

1246 Error bars represent standard error of mean (S.E.M.); \*\*\*\*P<0.0001, \*\*\*P<0.001, \*\*P<0.01,  
1247 \*P<0.05; n.s. not significant. Student's t-test (h). One-way ANOVA followed by Holm-Sidak's  
1248 test for multiple comparisons (i). h: Scramble (n=5), p65kd (n=5). i: CK (n=7), Scramble (n=5),  
1249 p65kd (n=6).

1250 **Figure 5. Ccl2 and Cxcl10 are secreted from DSB-bearing neurons to activate microglia.**

1251 **a.** Schematic for treating acute Cx3cr1-GFP slices with conditioned media from etoposide-treated  
1252 primary neuron cultures. Cultures were either treated with 50uM ETP or vehicle control (DMSO)  
1253 for six hours. In a separate condition, primary neurons were treated with 50uM ETP and 10uM  
1254 NF-kappaB Activation Inhibitor VI (IKK2 inhibitor). Cultures were washed with PBS after six  
1255 hours and media was replaced. After 24 hours, this media was applied to acute Cx3cr1-GFP slices  
1256 for 6 hours.

1257 **b.** Representative images of GFP in Cx3cr1-GFP acute slices treated with primary neuron  
1258 conditioned media.

1259 **c-f.** Quantification of branch length per microglia (c), end-points per microglia (d), soma area (e),  
1260 and number of microglia per image (f). Each data point represents the average measurement from  
1261 two images in one acute slice.

1262 **g,h.** Quantification of Cxcl10 (g) and Ccl2 (h) from conditioned media from control and etoposide-  
1263 treated primary neurons. Each datapoint represents one biological replicate.

1264 **i.** Schematic of ETP conditioned media experiment. Primary neurons were treated with either ETP  
1265 or DMSO for 6 hours, washed with PBS, then media was replaced. Cultures recovered for 24 hours  
1266 before conditioned media was collected. IgG, Ccl2, or Cxcl10 antibodies were used to  
1267 immunodeplete conditioned media before they were applied to Cx3cr1-GFP acute slices for 6  
1268 hours.

1269 **j.** Representative images of microglia from acute slices treated with different conditioned media.

1270 **k-n.** Quantification of (k) branch length per microgli (l) end-points per microglia, soma area (m),  
1271 and number of microglia per image (n). Each data point represents the average measurement from  
1272 two images in one acute slice.

1273 Error bars represent standard error of mean (S.E.M.); \*\*\*\*P<0.0001, \*\*\*P<0.001, \*\*P<0.01,  
1274 \*P<0.05, ns not significant. Two-way ANOVA followed by Sidak's test for multiple  
1275 comparisons (c-f). One-way ANOVA followed by Tukey's test for multiple comparisons (k-n).  
1276 Data are combined from two independent experiments (c-f, k-n). Data are combined from three  
1277 independent experiments (h,i).

1278 **Supplementary Figure 1.**

1279 **a.** Representative images of  $\gamma$ H2AX immunostaining in CK and CK-p25 cortex over a 6-week  
1280 timeline analysis.

1281 **b.** Average number of  $\gamma$ H2AX+ nuclei quantified per image at each timepoint. Each data point  
1282 represents one mouse.

1283 **c.** Flow cytometry dot plot of  $\gamma$ H2AX+ pATM+ nuclei in CK and CK-p25 cortex.

1284 **d.** Quantification of  $\gamma$ H2AX+ pATM+ nuclei in CK and CK-p25 cortex. Each data point  
1285 represents percent  $\gamma$ H2AX+ pATM+ nuclei for one mouse.

1286 **e.** Flow cytometry dot plot of  $\gamma$ H2AX, Camk2a, and NeuN immunoreactivity in nuclei from CK-  
1287 p25 cortex.  $\gamma$ H2AX+ Camk2a+ nuclei are gated in the left graph. This gated population is  
1288 highlighted in turquoise in the two graphs to the right.

1289 **f.** Camk2a median fluorescent intensity (MFI) is quantified for Glia, Baseline, Stage 1, and Stage  
1290 2 populations. MFI values are normalized to the Glia population.

1291 **g.** Representative dot plot of  $\gamma$ H2AX and NeuN immunoreactivity in 2-week induced CK-p25  
1292 cortex.

1293 **h.** Representative images of cell type and  $\gamma$ H2AX immunostaining in the 2wk-induced CK-p25  
1294 cortex. Celltype markers from left to right: neurons (NeuN), astrocytes (GFAP),  
1295 oligodendrocytes and oligodendrocyte precursor cells (Olig2), microglia (Iba1).

1296 **i.** Quantification of percent of  $\gamma$ H2AX-positive nuclei overlapping with each celltype stain. Each  
1297 dot represents one mouse. 50-100  $\gamma$ H2AX-positive nuclei were analyzed for each mouse and  
1298 celltype marker.

1299 **j.** Expression p25 in CK and CK-p25 gated populations. One datapoint represents fragments per  
1300 kilobase per million (FPKM) from a gated population from one mouse.

1301 **k.** Representative images of GFP,  $\gamma$ H2AX, and NeuN immunostaining from CK and CK-p25  
1302 cortex at the 2wk time point. Arrowheads indicate  $\gamma$ H2AX+ nuclei that express p25-GFP  
1303 regardless of NeuN immunoreactivity.

1304 **l.** Quantification of GFP expression across Stage 1 and Stage 2 populations. Each data point  
1305 represents percent  $\gamma$ H2AX+ population from Stage 1 or Stage 2 from one CK-p25 mouse.

1306 **m.** Representative images of Neurod1,  $\gamma$ H2AX, and NeuN from CK-p25 cortex at two-week  
1307 timepoint. White arrowhead indicates a  $\gamma$ H2AX+ nucleus with Neurod1 immunoreactivity but  
1308 not NeuN immunoreactivity.

1309 **n.** Quantification of Neurod1 expression across Stage 1 and Stage 2 populations. Each data point  
1310 represents percent  $\gamma$ H2AX+ population from Stage 1 or Stage 2 from one CK-p25 mouse.

1311 Error bars represent standard error of mean (S.E.M.); \*\*\*\*P<0.0001, \*\*\*P<0.001, \*P<0.05, n.s.  
1312 not significant; One-way ANOVA with Tukey's test for multiple comparisons (b,f). Student's T-  
1313 test (d). Data are averages of 4 images per mouse (b). Data are representative of at least 2  
1314 independent experiments (d). Data are pooled from 2 independent experiments (f).

1315 **Supplementary Figure 2.**

1316 **a.** Principle component analysis (PCA) of normalized gene expression matrix from CK and CK-  
1317 p25 subpopulations. Principle component 1 (PC1): 66% variance. Principle component 2 (PC2):  
1318 29% variance.

1319 **b.** Volcano plots of (top) Stage 1 vs. CK-p25 Baseline and (bottom) Stage 2 vs. CK-p25 Baseline  
1320 contrasts. Gray circles: non-significant (ns) transcripts. Red circles: transcripts with FDR adjusted  
1321 p-value <0.05 and log2fold change >|0.1|.

1322 **c.** Heatmap of differentially expressed genes from Stage 2 vs. CK-p25 Baseline and Stage 1 vs.  
1323 CK-p25 Baseline contrasts. Each column represents one mouse.

1324 **d.** Representative image of RNAscope probes for Camk2a (yellow) and Cxcl10 (magenta), and  
1325  $\gamma$ H2AX immunostaining (turquoise). To the right, the percent of  $\gamma$ H2AX-positive cells that are  
1326 Camk2a-positive (2 or more Camk2a puncta within the nucleus) are quantified. Each datapoint  
1327 represents one 2-week induced CK-p25 mouse. 17-42  $\gamma$ H2AX-positive cells were quantified for  
1328 each mouse. Turquoise outlines indicate  $\gamma$ H2AX-positive Camk2a-positive cells. Gray outlines  
1329 indicate  $\gamma$ H2AX-negative cells. White arrows indicate Camk2a-negative cells.

1330 **e.** Representative image of the RNAscope probe for Cxcl10 (magenta) combined with  $\gamma$ H2AX  
1331 immunostaining (turquoise). Imaging was performed on 1wk and 2wk CK-p25 cortices. To the  
1332 right, the number of  $\gamma$ H2AX-positive and  $\gamma$ H2AX-negative cells with 2 or more Cxcl10 puncta are  
1333 quantified. Each datapoint represents the average %Cxcl10-positive cells in one image from one  
1334 mouse. 4-3 images were taken per mouse. (CK-p25 1wk n=4, CK-p25 2wk n=4).

1335 **f.** Representative dot plots of  $\gamma$ H2AX and NeuN immunoreactivity in CK and CK-p25 mice at 1,  
1336 2, and 6 weeks induction. Stage 1 and Stage 2 percent population was calculated with respect to  
1337 the total  $\gamma$ H2AX-positive population.

1338 **g.** Stage 1 and Stage 2 percent population are quantified for each timepoint.

1339 Error bars represent standard error of mean (S.E.M.); \*\*\*\*P<0.0001, \*\*\*P<0.001, \*\*P<0.01,  
1340 \*P<0.05, n.s. not significant; Two-way ANOVA followed by Sidak's test for multiple comparisons  
1341 (e,g). Data are representative of 2 independent experiments (d). Data are pooled from four  
1342 independent experiments (g).

1343 **Supplementary Figure 3.**

1344 **a.** UMAPs labeled by genotype, mouse id, and timepoint.

1345 **b.** Distribution of Stage 2-gated nuclei in in silico cell type clusters, stratified by biological  
1346 replicate.

1347 **c.** Percent FANS label distribution across scRNA cell type clusters. Bargraph colors refer to FANS  
1348 gate label.

1349 **d.** Bulk RNA-seq gene signature enrichment in neuron cell type clusters. Stage 1 signature  
1350 enrichment (left), Stage 2 signature enrichment (middle), and immune genes from Stage 2  
1351 enrichment (right). Each datapoint indicates average gene expression across all cells from one  
1352 mouse. Only CK-p25 mice were used for this analysis.

1353 \*\*\*\*P<0.0001, \*\*\*P<0.001, \*\*P<0.01, \*P<0.05, n.s. not significant; One-way ANOVA with  
1354 Tukey's test for multiple comparisons (d).



1355 **Supplementary Figure 4.**

1356 **a.** Representative images of celltype immunostaining in DIV13 primary neuron cultures. The  
1357 percent nuclei that stained positively for each celltype marker are quantified on the right. Three  
1358 images were analyzed for each marker.

1359 **b.** PCA plot of normalized gene expression matrix from ETP and DMSO-treated neurons. Principle  
1360 component 1 (PC1): 75% variance. Principle component 2 (PC2): 7% variance.

1361 **c.** Volcano plot of ETP vs. DMSO contrast. Gray circles: non-significant (ns) transcripts. Red  
1362 circles: transcripts with FDR adjusted p-value  $<0.05$  and  $\log_2$  fold change  $>|0.1|$ .

1363 **d.** Heatmap of differentially expressed genes from ETP vs. DMSO contrast. Columns represent  
1364 biological replicates.

1365 **e.** Quantification of Stage 1 and Stage 2 signature enrichment (from bulk RNAseq) in DMSO and  
1366 ETP-treated neurons. Each data point represents one biological replicate.

1367 **f.** Number of Ccl2 puncta (magenta) are quantified for Rbfox3-positive nuclei (2 or more Rbfox3  
1368 puncta within or surrounding the nucleus, yellow), and Rbfox3-negative nuclei. Cyan circles  
1369 outline nuclei. Each datapoint represents one nucleus.

1370 Error bars represent standard error of mean (S.E.M.); \*\*\*\*P $<0.0001$ , \*\*\*P $<0.001$ , \*P $<0.05$ .  
1371 Wilcoxon test (e). Student's t-test (f). Data are representative of two independent experiments (a,f).

1372 **Supplementary Figure 5.**

- 1373 **a.** Flow cytometry dot plot of  $\gamma$ H2AX gating for human NeuN<sup>+</sup> and NeuN<sup>-</sup> nuclei. Percent total  
1374 population is indicated for each gating box.
- 1375 **b.** Correlation heatmap of  $\gamma$ H2AX<sup>+</sup> and  $\gamma$ H2AX<sup>-</sup>/NeuN<sup>+</sup> and NeuN<sup>-</sup> bulk RNAseq libraries from  
1376 postmortem temporal cortex.
- 1377 **c.** PCA plot of normalized gene expression from  $\gamma$ H2AX<sup>+</sup> and  $\gamma$ H2AX<sup>-</sup>/NeuN<sup>+</sup> and NeuN<sup>-</sup>  
1378 samples.
- 1379 **d.** Quantification of normalized neuronal and glial marker gene expression in NeuN<sup>+</sup> and NeuN<sup>-</sup>  
1380 samples. Mean gene expression is compared with a Wilcoxon test. Gene set enrichment was  
1381 calculated using Gene Set Variation Analysis (GSVA).
- 1382 **e.** Gene expression heatmap of top five marker genes for major brain cell types. Each column  
1383 represents one human sample.
- 1384 **f.** Gene expression heatmap of all marker genes for major brain cell types. Each column represents  
1385 one human sample.
- 1386 **g.** Distribution of logFC values for Stage 1 genes (light blue), Stage 2 genes (dark blue), and other  
1387 genes (red). LogFC values are from  $\gamma$ H2AX<sup>+</sup> vs  $\gamma$ H2AX<sup>-</sup> comparison. Mean LogFC for each gene  
1388 set are compared with a Wilcoxon test.
- 1389 **h.** Heatmap of ETP and  $\gamma$ H2AX<sup>+</sup> and  $\gamma$ H2AX<sup>-</sup> human neuronal nuclei transcriptional correlation.  
1390 Excitatory (Ex), Inhibitory (In), Astrocyte (Ast), Microglia (Mic), Oligodendrocyte (Oli),  
1391 Oligodendrocyte Precursor Cells (OPC), Endothelial (Endo).

1392 **Supplementary Figure 6.**

1393 **a.** Schematic for binning  $\gamma$ H2AX expression in NeuN-positive cells, and nuclear p65  
1394 quantification. For each individual, the median  $\gamma$ H2AX expression in NeuN-positive cells was  
1395 calculated. Cells were then binned as  $\gamma$ H2AX high or  $\gamma$ H2AX low based off of median  $\gamma$ H2AX  
1396 expression. Nuclear p65 intensity was then calculated for all cells.

1397 **b.** Raw data from the four AD individuals used for analysis.

1398 Error bars represent standard error of mean (S.E.M.); \*\*\*\*P<0.0001, \*\*\*P<0.001, \*\*P<0.01,  
1399 \*P<0.05, ns not significant. A t-test was performed to compare mean p65 intensity between  
1400  $\gamma$ H2AX low and  $\gamma$ H2AX high cells.

1401 **Supplementary Figure 7.**

1402 **a.** Distribution of capture areas amongst spatial clusters for each sample. The y-axis refers to  
1403 number capture areas. Colors refer to spatial cluster id.

1404 **b.** Distribution of samples by spatial cluster. Colors refer to sample id.

1405 **c.** Top:  $\gamma$ H2AX immunostaining for each CK-p25 section. Bottom: the corresponding capture  
1406 areas identified as  $\gamma$ H2AX-positive are marked in yellow.  $\gamma$ H2AX-negative capture areas are  
1407 marked in purple.

1408 **Supplementary Figure 8.**

- 1409 **a.** Gene set enrichment analysis of  $\gamma$ H2AX-positive capture area DEGs. DEGs were tested for  
1410 the enrichment of the reactive microglia signature characterized in Mathys et al., 2019. The  
1411 analysis was first performed for all  $\gamma$ H2AX-positive capture areas, then for individual clusters  
1412 comprised of 20% or more  $\gamma$ H2AX-positive capture areas. Normalized enrichment score (NES).
- 1413 **b.** Percent  $\gamma$ H2AX-positive capture areas by spatial cluster. Orange indicates  $\gamma$ H2AX-positive  
1414 capture areas. Blue indicates  $\gamma$ H2AX-negative capture areas.

1415 **Supplementary Figure 9.**

1416 **a.** Distribution of spatial clusters for each sample.

1417 **b-d.** Expression of reactive microglia and DSB-bearing neuron genes (b) *Ifitm3*, (c) *H2-D1*, and  
1418 (c) *Cxcl10* for each sample.

1419 **e.** Distribution of  $\gamma$ H2AX-positive capture areas for each CK-p25 sample.

1420 **Supplementary Figure 10.**

1421 **a.** Representative images of cell type specific immunostaining and RFP immunostaining in  
1422 scramble and p65kd cortex. Top to bottom, left to right: NeuN=neurons, Iba1=microglia,  
1423  $\gamma$ H2AX= $\gamma$ H2AX+ cells, Olig2=oligodendrocytes and oligodendrocyte precursor cells,  
1424 GFAP=astrocytes.

1425 **b.** Quantification of cell type distribution of RFP+ cells. Total number of RFP+ cells are quantified  
1426 per image, then the fraction co-stained for a celltype marker are calculated. Each datapoint  
1427 represents one mouse.

1428 **c.** P65 and RFP immunostaining in scramble and p65kd CK-p25 cortex.

1429 **d.** Quantification of p65 mean intensity. Analysis was performed on three animals, two sections  
1430 each. Scramble n=113 cells, p65kd n=103 cells.

1431 **e.** qRT-PCR of p65 in RFP+ NeuN+ nuclei from scramble and shp65-treated CK-p25 mice.

1432 **f.** Representative images of  $\gamma$ H2AX immunostaining in p65 kd and scramble CK-p25 cortex.

1433 **g.** Number of  $\gamma$ H2AX+ per image are quantified. Each data point represents one mouse.

1434 Error bars represent standard error of mean (S.E.M.); \*\*\*\*P<0.0001, \*\*\*P<0.001, \*\*P<0.01,  
1435 \*P<0.05, n.s. not significant. Student's t-test (d,e,g).

1436 **Supplementary Figure 11.**

1437 **a.** Sorting schematic for RFP+  $\gamma$ H2AX+ and  $\gamma$ H2AX- neurons. 30,000 nuclei were collected for  
1438 each gate for each animal.

1439 **b.** Representative images of Ccl2 RNAscope combined with  $\gamma$ H2AX immunofluorescence in  
1440 Scramble and p65kd cortex.

1441 **c.** Quantification of Ccl2 puncta per  $\gamma$ H2AX+ cell. Each datapoint represents one cell (n=197 for  
1442 scramble, n=157 for p65 kd). 20-40 cells were analyzed per mouse.

1443 **d.** Sorting schematic for Pu.1+ nuclei for RNA-sequencing.


1444 **e.** Quantification of total percent Pu.1+. One datapoint represents one mouse.

1445 **f.** PCA plot of normalized gene expression matrix from Pu.1+ bulk RNA-sequencing.

1446 **g.** Volcano plot from P65 vs. Scramble contrast.

1447 Error bars represent standard error of mean (S.E.M.); \*\*\*\*P<0.0001, \*\*\*P<0.001, \*\*P<0.01,  
1448 \*P<0.05, ns not significant. One-way ANOVA followed by Tukey's test for multiple comparisons  
1449 (e).





**Figure 1. Neurons marked by DNA DSBs activate inflammatory signaling at early stages of neurodegeneration.**

**a.** Flow cytometry dot plots of  $\gamma$ H2AX+ nuclei from CK and CK-p25 cortex.  $\gamma$ H2AX+ are highlighted in turquoise, and percent total population is indicated above the gating box.

**b.** CK-p25 mice were taken off dox for 1 through 6 weeks, then cortical nuclei were extracted and stained for  $\gamma$ H2AX. Each datapoint represents percent  $\gamma$ H2AX+ nuclei from one mouse cortex.

**c.** RNA seq workflow for the gated populations. Bulk RNA-seq: Cortices were extracted from CK and CK-p25 mice (n=2 per genotype for bulk RNA-seq, 2-week timepoint only). Tissue was homogenized, then nuclei were extracted and stained for NeuN and  $\gamma$ H2AX. 50,000 nuclei were sorted from each gated population. snRNA-seq: Cortices were extracted from CK and CK-p25 mice (n=3 per genotype\*timepoint for SMART-seq, 1-week and 2-week timepoints). Tissue was homogenized, then nuclei were extracted and stained for NeuN and  $\gamma$ H2AX. 48 nuclei were sorted for each gated CK-p25 population per mouse, and 32 nuclei were sorted for each gated CK population per mouse.

**d.** Differential gene ontology terms from gene set enrichment analysis (GSEA) of bulk RNAseq data. Left column depicts GSEA results from Stage 1 vs. CK-p25 Baseline contrast. Right column depicts GSEA results from Stage 2 vs. CK-p25 Baseline contrast. Color indicates normalized enrichment score (NES). Size indicates false discovery rate (FDR).

**e.** Heatmap of differentially expressed genes belonging to inflammatory gene sets from bulk RNA-seq data. Each column represents one mouse. Gene sets are organized by biological function.

**f.** (left): Representative images of Ccl2 RNAscope combined with  $\gamma$ H2AX immunofluorescent staining. Imaging was performed on 1wk and 2wk CK-p25 cortex. (right): Quantification of number of  $\gamma$ H2AX+ and  $\gamma$ H2AX- cells with  $\leq 2$  Ccl2 puncta. Each datapoint represents average %Ccl2-positive cells in one image from one mouse. 4-3 images were taken per mouse. (Ccl2 1wk n=4, Ccl2 2wk n=5)

**g.** Representative image of p65 immunostaining in CK-p25 cortex at two-week timepoint. White arrowheads indicate  $\gamma$ H2AX+ nuclei with nuclear p65 immunoreactivity. Quantification of p65 mean intensity for  $\gamma$ H2AX+ and  $\gamma$ H2AX- nuclei. Each data point represents the average p65 nuclear mean gray value of 20-60 nuclei from one mouse.


**h.** UMAP of gated populations from CK and CK-p25 cortex at 1-week and 2-week timepoints. Colors indicate cell type annotation.

**i.** Marker gene expression for each cell type cluster. Columns represent 985 individual cells ordered by cell type cluster.

**j.** Trajectory analysis of Ex0, 1, 2, 3, and Stage 2 neurons. Cells from each cluster (indicated by color annotation) are ordered across pseudotime (indicated by color gradient).

**k.** Trajectory analysis of Ex0, 1, 2, 3, and Stage 2 neurons. Smoothed gene signature expression across pseudotime. Stage 1=Significantly upregulated genes from Stage 1 vs. Baseline contrast. Stage 2= Significantly upregulated genes from Stage 2 vs. Baseline contrast. Immune= Genes belonging to immune gene ontologies that were significantly upregulated in Stage 2 neurons. padj<0.05, Log<sub>2</sub> fold-change  $\geq 1.0$ .


Error bars represent standard error of mean (S.E.M.); \*\*\*\*P<0.0001, \*\*\*P<0.001, \*\*P<0.01, \*P<0.05; One-way ANOVA with Tukey's test for multiple comparisons (b,f). Two-way ANOVA followed by Sidak's test for multiple comparisons (g). Data are pooled from 4 independent experiments (b). Data are representative of two independent experiments (f,g).



**Figure 2. Induction of DNA DSBs is sufficient to elicit immune pathway signaling in neuron primary culture.**

- a.** Top: Representative images of NeuN and  $\gamma$ H2AX immunostaining in ETP and vehicle-treated primary cultures.  $\gamma$ H2AX immunoreactivity is quantified for each condition. Each data point represents  $\gamma$ H2AX mean gray value for one nucleus in the representative image. Bottom: Representative images of p65 immunostaining in ETP and vehicle-treated primary cultures. p65 immunoreactivity is quantified for each condition. Each data point represents p65 mean gray value for one nucleus in the representative image.
- b.** Schematic of etoposide (ETP) treatment. DIV13 neuron primary culture were treated with either 50uM ETP or vehicle control (DMSO) for 6 hours. mRNA was extracted from the cultures and sequenced.
- c.** Differential gene ontology terms identified through gene set enrichment analysis (GSEA) from ETP vs. DMSO contrast.
- d.** Heatmap of Stage 1 and Stage 2 signature enrichment (from bulk RNAseq) in DMSO and ETP-treated neurons.
- e.** Venn diagram of significantly upregulated protein-coding genes from ETP-treated neurons and Stage 1 and Stage 2 gene signatures. Percentages are in reference to the total number of unique genes from all three gene sets. Example genes are shown to the right. Genes overlapping in ETP and Stage 2 are in turquoise. Genes overlapping in ETP, Stage 2, and Stage 1 are in magenta. The area of the circles are in proportion to the size of the gene sets.
- f.** Representative images of NeuN and  $\gamma$ H2AX immunostaining from 10 Gy and 0 Gy x-ray irradiation treated primary neurons.
- g.** qRT-PCR of *Cdkn1a*, *Ccl2*, and *Cxcl10* in 10 Gy irradiated primary neurons. Each datapoint represents one biological replicate.


Error bars represent standard error of mean (S.E.M.); \*\*\*\* $P < 0.0001$ , \*\*\* $P < 0.001$ . Student's T-test (a,g). Data are representative of 3 independent experiments (a). Data are representative of 2 independent experiments (g).



**Figure 3. Inflammatory signaling in DSB-bearing neurons is positively correlated with Alzheimer's disease pathology.**

**a.** Schematic of the Stage 2 signature analysis in the snRNA-seq dataset from Mathys et al., 2019.  
**b.** Quantification of Stage 2 signature correlation with global pathology in celltype clusters from Mathys et al., 2019. It was tested if stage 2 genes were significantly and positively correlated with the global pathology metric for each major celltype. The  $-\log_{10}$  p-value for these tests are shown in the histogram. The dashed line indicates a p-value of 0.01 after Bonferroni correction for multiple testing. Excitatory neurons (Ex), Inhibitory neurons (In), Astrocytes (Ast), Oligodendrocytes (Oli), Oligodendrocyte precursor cells (Opc), Microglia (Mic).  
**c.** Stage 2 signature genes ranked by their correlation with global pathology in excitatory neurons. Stage 2 genes with positive correlation are shown with red circles.  
**d.** Gene ontology enrichment of Stage 2 signature genes positively correlated with global pathology.  
**e.** Schematic of  $\gamma$ H2AX+ nuclei sorting from AD and non-AD brain tissue.  
**f.** Heatmap of Stage 1 and Stage 2 signature enrichment in  $\gamma$ H2AX+ and  $\gamma$ H2AX- human NeuN+ nuclei.  
**g-i.** Quantification of Stage 1 and Stage 2 signature enrichment in  $\gamma$ H2AX+ and  $\gamma$ H2AX- human NeuN+ nuclei samples by FANS gate (g), and FANS gate and disease status (h,i).  
**j.** Representative image of  $\gamma$ H2AX, p65, and NeuN in the AD brain. Left: two NeuN-positive nuclei are outlined (white dashed line). Right: magnification of the two outlined nuclei. Top nucleus (A) represents low  $\gamma$ H2AX burden, bottom nucleus (B) represents high  $\gamma$ H2AX burden.  
**k.** Quantification of p65 nuclear enrichment in low and high  $\gamma$ H2AX-burdened neurons. Each dot represents the average of 23-41 NeuN+ nuclei per individual.

Error bars represent standard error of mean (S.E.M.); \*\*\*\*P<0.0001, \*\*\*P<0.001, \*\*P<0.01, \*P<0.05, ns not significant. T-test (k). Wilcoxon test (g-i).



**Figure 4. Immune signaling in neurons recruits and activates microglia.**

**a.** Schematic of spatial transcriptomics experiment. CK (n=3) and CK-p25 (n=4) were induced for two weeks. Coronal brain sections were stained and imaged for  $\gamma$ H2AX, then sequenced.

**b.** UMAP of capture areas from all samples. Leiden clusters are indicated by color and number. Each dot represents one capture area.

**c.** Leiden clusters superimposed onto a CK-p25 brain slice used for spatial transcriptomics.

**d.** UMAP indicating the density of  $\gamma$ H2AX-positive capture areas.

**e.**  $\gamma$ H2AX-positive capture areas identified in one CK-p25 brain slice.  $\gamma$ H2AX-positive capture areas are shown in red. Captures are superimposed over DAPI staining (white).

**f.** Spatial clusters,  $\gamma$ H2AX-positive capture areas, and reactive microglia signature gene expression in one CK-p25 sample.

**g.** Schematic of neuronal p65 knock-down experiment. CK-p25 mice receive retro-orbital injections of scramble shRNA-RFP AAV or *shp65*-RFP AAV. CK mice received retro-orbital injections of PBS. Mice were allowed to recover for two weeks before being taken off dox. Brains were collected for subsequent analysis at the two week timepoint.

**h.** qRT-PCR of immune genes in sorted  $\gamma$ H2AX+ nuclei.

**i.** Representative images of Iba1 immunostaining in CK, Scramble, and p65kd cortex.


**j.** Quantification of (left to right): Iba1+ soma area, number Iba1+ per image, average branch length per Iba1+ cell, and number end-points per Iba1+ cell. Each data point represents one image. Two images were taken per mouse.

**k.** Heat map of differentially expressed genes from P65 vs. Scramble contrast. Each column represents one mouse.

**l.** Upregulated and downregulated gene ontology (biological pathway) terms identified through gene set enrichment analysis (GSEA) from p65 kd vs. scramble contrast.

**m.** Heatmap of significantly upregulated and downregulated genes in Pu.1+ nuclei from p65 kd cortex compared to Pu.1+ nuclei from scramble cortex. Each row represents gene expression from one mouse.

Error bars represent standard error of mean (S.E.M.); \*\*\*\*P<0.0001, \*\*\*P<0.001, \*\*P<0.01, \*P<0.05; n.s. not significant. Student's t-test (h). One-way ANOVA followed by Holm-Sidak's test for multiple comparisons (i). h: Scramble (n=5), p65kd (n=5). i: CK (n=7), Scramble (n=5), p65kd (n=6).



**Figure 5. Ccl2 and Cxcl10 are secreted from DSB-bearing neurons to activate microglia.**

**a.** Schematic for treating acute Cx3cr1-GFP slices with conditioned media from etoposide-treated primary neuron cultures. Cultures were either treated with 50uM ETP or vehicle control (DMSO) for six hours. In a separate condition, primary neurons were treated with 50uM ETP and 10uM NF-kappaB Activation Inhibitor VI (IKK2 inhibitor). Cultures were washed with PBS after six hours and media was replaced. After 24 hours, this media was applied to acute Cx3cr1-GFP slices for 6 hours.

**b.** Representative images of GFP in Cx3cr1-GFP acute slices treated with primary neuron conditioned media.

**c-f.** Quantification of branch length per microglia (c), end-points per microglia (d), soma area (e), and number of microglia per image (f). Each data point represents the average measurement from two images in one acute slice.


**g,h.** Quantification of Cxcl10 (g) and Ccl2 (h) from conditioned media from control and etoposide-treated primary neurons. Each datapoint represents one biological replicate.

**i.** Schematic of ETP conditioned media experiment. Primary neurons were treated with either ETP or DMSO for 6 hours, washed with PBS, then media was replaced. Cultures recovered for 24 hours before conditioned media was collected. IgG, Ccl2, or Cxcl10 antibodies were used to immunodeplete conditioned media before they were applied to Cx3cr1-GFP acute slices for 6 hours.

**j.** Representative images of microglia from acute slices treated with different conditioned media.

**k-n.** Quantification of (k) branch length per microglia (l) end-points per microglia, soma area (m), and number of microglia per image (n). Each data point represents the average measurement from two images in one acute slice.


Error bars represent standard error of mean (S.E.M.); \*\*\*\*P<0.0001, \*\*\*P<0.001, \*\*P<0.01, \*P<0.05, ns not significant. Two-way ANOVA followed by Sidak's test for multiple comparisons (c-f). One-way ANOVA followed by Tukey's test for multiple comparisons (k-n). Data are combined from two independent experiments (c-f, k-n). Data are combined from three independent experiments (h,i).



**Supplementary Figure 1.**

- a.** Representative images of γH2AX immunostaining in CK and CK-p25 cortex over a 6-week timeline analysis.
- b.** Average number of γH2AX+ nuclei quantified per image at each timepoint. Each data point represents one mouse.
- c.** Flow cytometry dot plot of γH2AX+ pATM+ nuclei in CK and CK-p25 cortex.
- d.** Quantification of γH2AX+ pATM+ nuclei in CK and CK-p25 cortex. Each data point represents percent γH2AX+ pATM+ nuclei for one mouse.
- e.** Flow cytometry dot plot of γH2AX, Camk2a, and NeuN immunoreactivity in nuclei from CK-p25 cortex. γH2AX+ Camk2a+ nuclei are gated in the left graph. This gated population is highlighted in turquoise in the two graphs to the right.
- f.** Camk2a median fluorescent intensity (MFI) is quantified for Glia, Baseline, Stage 1, and Stage 2 populations. MFI values are normalized to the Glia population.
- g.** Representative dot plot of γH2AX and NeuN immunoreactivity in 2-week induced CK-p25 cortex.
- h.** Representative images of cell type and γH2AX immunostaining in the 2wk-induced CK-p25 cortex. Celltype markers from left to right: neurons (NeuN), astrocytes (GFAP), oligodendrocytes and oligodendrocyte precursor cells (Olig2), microglia (Iba1).
- i.** Quantification of percent of γH2AX-positive nuclei overlapping with each celltype stain. Each dot represents one mouse. 50-100 γH2AX-positive nuclei were analyzed for each mouse and celltype marker.
- j.** Expression p25 in CK and CK-p25 gated populations. One datapoint represents fragments per kilobase per million (FPKM) from a gated population from one mouse.
- k.** Representative images of GFP, γH2AX, and NeuN immunostaining from CK and CK-p25 cortex at the 2wk time point. Arrowheads indicate γH2AX+ nuclei that express p25-GFP regardless of NeuN immunoreactivity.
- l.** Quantification of GFP expression across Stage 1 and Stage 2 populations. Each data point represents percent γH2AX+ population from Stage 1 or Stage 2 from one CK-p25 mouse.
- m.** Representative images of Neurod1, γH2AX, and NeuN from CK-p25 cortex at two-week timepoint. White arrowhead indicates a γH2AX+ nucleus with Neurod1 immunoreactivity but not NeuN immunoreactivity.
- n.** Quantification of Neurod1 expression across Stage 1 and Stage 2 populations. Each data point represents percent γH2AX+ population from Stage 1 or Stage 2 from one CK-p25 mouse.


Error bars represent standard error of mean (S.E.M.); \*\*\*\*P<0.0001, \*\*\*P<0.001, \*P<0.05, n.s. not significant; One-way ANOVA with Tukey's test for multiple comparisons (b,f). Student's T-test (d). Data are averages of 4 images per mouse (b). Data are representative of at least 2 independent experiments (d). Data are pooled from 2 independent experiments (f).



### Supplementary Figure 2.

- a.** Principle component analysis (PCA) of normalized gene expression matrix from CK and CK-p25 subpopulations. Principle component 1 (PC1): 66% variance. Principle component 2 (PC2): 29% variance.
- b.** Volcano plots of (top) Stage 1 vs. CK-p25 Baseline and (bottom) Stage 2 vs. CK-p25 Baseline contrasts. Gray circles: non-significant (ns) transcripts. Red circles: transcripts with FDR adjusted p-value < 0.05 and  $\log_2$  fold change > |0.1|.
- c.** Heatmap of differentially expressed genes from Stage 2 vs. CK-p25 Baseline and Stage 1 vs. CK-p25 Baseline contrasts. Each column represents one mouse.
- d.** Representative image of RNAscope probes for *Camk2a* (yellow) and *Cxcl10* (magenta), and  $\gamma$ H2AX immunostaining (turquoise). To the right, the percent of  $\gamma$ H2AX-positive cells that are *Camk2a*-positive (2 or more *Camk2a* puncta within the nucleus) are quantified. Each datapoint represents one 2-week induced CK-p25 mouse. 17-42  $\gamma$ H2AX-positive cells were quantified for each mouse. Turquoise outlines indicate  $\gamma$ H2AX-positive *Camk2a*-positive cells. Gray outlines indicate  $\gamma$ H2AX-negative cells. White arrows indicate *Camk2a*-negative cells.
- e.** Representative image of the RNAscope probe for *Cxcl10* (magenta) combined with  $\gamma$ H2AX immunostaining (turquoise). Imaging was performed on 1wk and 2wk CK-p25 cortices. To the right, the number of  $\gamma$ H2AX-positive and  $\gamma$ H2AX-negative cells with 2 or more *Cxcl10* puncta are quantified. Each datapoint represents the average %*Cxcl10*-positive cells in one image from one mouse. 4-3 images were taken per mouse. (CK-p25 1wk n=4, CK-p25 2wk n=4).
- f.** Representative dot plots of  $\gamma$ H2AX and NeuN immunoreactivity in CK and CK-p25 mice at 1, 2, and 6 weeks induction. Stage 1 and Stage 2 percent population was calculated with respect to the total  $\gamma$ H2AX-positive population.
- g.** Stage 1 and Stage 2 percent population are quantified for each timepoint.

Error bars represent standard error of mean (S.E.M.); \*\*\*\*P<0.0001, \*\*\*P<0.001, \*\*P<0.01, \*P<0.05, n.s. not significant; Two-way ANOVA followed by Sidak's test for multiple comparisons (e,g). Data are representative of 2 independent experiments (d). Data are pooled from four independent experiments (g).



### Supplementary Figure 3.

a. UMAPs labeled by genotype, mouse id, and timepoint.


b. Distribution of Stage 2-gated nuclei in *in silico* cell type clusters, stratified by biological replicate.

c. Percent FANS label distribution across scRNA cell type clusters. Bargraph colors refer to FANS gate label.

d. Bulk RNA-seq gene signature enrichment in neuron cell type clusters. Stage 1 signature enrichment (left), Stage 2 signature enrichment (middle), and immune genes from Stage 2 enrichment (right). Each datapoint indicates average gene expression across all cells from one mouse. Only CK-p25 mice were used for this analysis.

\*\*\*\* $P < 0.0001$ , \*\*\* $P < 0.001$ , \*\* $P < 0.01$ , \* $P < 0.05$ , n.s. not significant; One-way ANOVA with Tukey's test for multiple comparisons (d).






#### Supplementary Figure 4.

- a.** Representative images of celltype immunostaining in DIV13 primary neuron cultures. The percent nuclei that stained positively for each celltype marker are quantified on the right. Three images were analyzed for each marker.
- b.** PCA plot of normalized gene expression matrix from ETP and DMSO-treated neurons. Principle component 1 (PC1): 75% variance. Principle component 2 (PC2): 7% variance.
- c.** Volcano plot of ETP vs. DMSO contrast. Gray circles: non-significant (ns) transcripts. Red circles: transcripts with FDR adjusted p-value < 0.05 and  $\text{log}_2$  fold change > |0.1|.
- d.** Heatmap of differentially expressed genes from ETP vs. DMSO contrast. Columns represent biological replicates.
- e.** Quantification of Stage 1 and Stage 2 signature enrichment (from bulk RNAseq) in DMSO and ETP-treated neurons. Each data point represents one biological replicate.
- f.** Number of *Ccl2* puncta (magenta) are quantified for *Rbfox3*-positive nuclei (2 or more *Rbfox3* puncta within or surrounding the nucleus, yellow), and *Rbfox3*-negative nuclei. Cyan circles outline nuclei. Each datapoint represents one nucleus.



Error bars represent standard error of mean (S.E.M.); \*\*\*\* $P < 0.0001$ , \*\*\* $P < 0.001$ , \* $P < 0.05$ . Wilcoxon test (e). Student's t-test (f). Data are representative of two independent experiments (a,f).



**Supplementary Figure 5.**

- a.** Flow cytometry dot plot of  $\gamma$ H2AX gating for human NeuN+ and NeuN- nuclei. Percent total population is indicated for each gating box.
- b.** Correlation heatmap of  $\gamma$ H2AX+ and  $\gamma$ H2AX-/NeuN+ and NeuN- bulk RNAseq libraries from postmortem temporal cortex.
- c.** PCA plot of normalized gene expression from  $\gamma$ H2AX+ and  $\gamma$ H2AX-/NeuN+ and NeuN- samples.
- d.** Quantification of normalized neuronal and glial marker gene expression in NeuN+ and NeuN- samples. Mean gene expression is compared with a Wilcoxon test. Gene set enrichment was calculated using Gene Set Variation Analysis (GSVA).
- e.** Gene expression heatmap of top five marker genes for major brain cell types. Each column represents one human sample.
- f.** Gene expression heatmap of all marker genes for major brain cell types. Each column represents one human sample.
- g.** Distribution of logFC values for Stage 1 genes (light blue), Stage 2 genes (dark blue), and other genes (red). LogFC values are from  $\gamma$ H2AX+ vs  $\gamma$ H2AX- comparison. Mean LogFC for each gene set are compared with a Wilcoxon test.
- h.** Heatmap of ETP and  $\gamma$ H2AX+ and  $\gamma$ H2AX- human neuronal nuclei transcriptional correlation.

Excitatory (Ex), Inhibitory (In), Astrocyte (Ast), Microglia (Mic), Oligodendrocyte (Oli), Oligodendrocyte Precursor Cells (OPC), Endothelial (Endo).




**Supplementary Figure 6.**


**a.** Schematic for binning  $\gamma$ H2AX expression in NeuN-positive cells, and nuclear p65 quantification. For each individual, the median  $\gamma$ H2AX expression in NeuN-positive cells was calculated. Cells were then binned as  $\gamma$ H2AX high or  $\gamma$ H2AX low based off of median  $\gamma$ H2AX expression. Nuclear p65 intensity was then calculated for all cells.

**b.** Raw data from the four AD individuals used for analysis.

Error bars represent standard error of mean (S.E.M.); \*\*\*\* $P < 0.0001$ , \*\*\* $P < 0.001$ , \*\* $P < 0.01$ , \* $P < 0.05$ , ns not significant. A t-test was performed to compare mean p65 intensity between  $\gamma$ H2AX low and  $\gamma$ H2AX high cells.



**c** 2-week CK-p25 Sections for Visium Spatial Gene Expression



**Supplementary Figure 7.**


**a.** Distribution of capture areas amongst spatial clusters for each sample. The y-axis refers to number capture areas. Colors refer to spatial cluster id.

**b.** Distribution of samples by spatial cluster. Colors refer to sample id.

**c.** Top:  $\gamma$ H2AX immunostaining for each CK-p25 section. Bottom: the corresponding capture areas identified as  $\gamma$ H2AX-positive are marked in yellow.  $\gamma$ H2AX-negative capture areas are marked in purple.

Mathys et al., 2017 microglia signature enrichment  
 $\gamma$ H2AX-positive capture areas vs.  $\gamma$ H2AX-negative capture areas:


a



**Supplementary Figure 8.**

a. Gene set enrichment analysis of  $\gamma$ H2AX-positive capture area DEGs. DEGs were tested for the enrichment of the reactive microglia signature characterized in Mathys et al., 2017. The analysis was first performed for all  $\gamma$ H2AX-positive capture areas, then for individual clusters comprised of 20% or more  $\gamma$ H2AX-positive capture areas. Normalized enrichment score (NES).

b. Percent  $\gamma$ H2AX-positive capture areas by spatial cluster. Orange indicates  $\gamma$ H2AX-positive capture areas. Blue indicates  $\gamma$ H2AX-negative capture areas.




**Supplementary Figure 9.**

**a.** Distribution of spatial clusters for each sample.

**b-d.** Expression of reactive microglia genes and DSB-bearing neuron genes (b) *Ifitm3*, (c) *H2-D1*, and (d) *Cxcl10* for each sample.


**e.** Distribution of  $\gamma$ H2AX-positive capture areas for each CK-p25 sample.



### Supplementary Figure 10.

- a.** Representative images of cell type specific immunostaining and RFP immunostaining in scramble and p65kd cortex. Top to bottom, left to right: NeuN=neurons, Iba1=microglia, γH2AX=γH2AX+ cells, Olig2=oligodendrocytes and oligodendrocyte precursor cells, GFAP=astrocytes.
- b.** Quantification of cell type distribution of RFP+ cells. Total number of RFP+ cells are quantified per image, then the fraction co-stained for a celltype marker are calculated. Each datapoint represents one mouse.
- c.** P65 and RFP immunostaining in scramble and p65kd CK-p25 cortex.
- d.** Quantification of p65 mean intensity. Analysis was performed on three animals, two sections each. Scramble n=113 cells, p65kd n=103 cells.
- e.** qRT-PCR of p65 in RFP+ NeuN+ nuclei from scramble and shp65-treated CK-p25 mice.
- f.** Representative images of γH2AX immunostaining in p65 kd and scramble CK-p25 cortex.
- g.** Number of γH2AX+ per image are quantified. Each data point represents one mouse.

Error bars represent standard error of mean (S.E.M.); \*\*\*\*P<0.0001, \*\*\*P<0.001, \*\*P<0.01, \*P<0.05, n.s. not significant. Student's t-test (d,e,g).



### Supplementary Figure 11.

- Sorting schematic for RFP+  $\gamma$ H2AX+ and  $\gamma$ H2AX- neurons. 30,000 nuclei were collected for each gate for each animal.
- Representative images of Ccl2 RNAscope combined with  $\gamma$ H2AX immunofluorescence in Scramble and p65kd cortex.
- Quantification of Ccl2 puncta per  $\gamma$ H2AX+ cell. Each datapoint represents one cell (n=197 for scramble, n=157 for p65 kd). 20-40 cells were analyzed per mouse.
- Sorting schematic for Pu.1+ nuclei for RNA-sequencing.
- Quantification of total percent Pu.1+. One datapoint represents one mouse.
- PCA plot of normalized gene expression matrix from Pu.1+ bulk RNA-sequencing.
- Volcano plot from P65 vs. Scramble contrast.

Error bars represent standard error of mean (S.E.M.); \*\*\*\*P<0.0001, \*\*\*P<0.001, \*\*P<0.01, \*P<0.05, ns not significant. One-way ANOVA followed by Tukey's test for multiple comparisons (e).



**Supplementary Table 3**

<b>ADRC #</b>	<b>Clinical Diagnosis</b>	<b>SEX</b>	<b>PMI</b>	<b>AGE</b>	<b>Braak</b>	<b>Demented?</b>
2018	Control	F	24	92	II	No
2068	Control	F	9	79	II	No
2088	Control	M	24	65	I	No
2136	AD	F	24	87	VI	Yes
2166	AD	F	21	71	VI	Yes
2151	AD	M	23	81	VI	Yes

Clinical Diagnosis = Diagnosis at time of death based on Clinician and Pathology fellow's knowledge

SEX F=Female, M=Male

PMI = Post mortem interval (in hours)

AGE = Age at death (in hours)

Braak = Braack stage

## Supplementary Table 4

ID	apoe_genotype	cogdx	age_death	educ	msex	braaksc	fixation_interval	pml	amyloid	plaq_d	plaq_n	nft	tangles
21159840	44	4	82.71047228	16	0	5	NA	2.16666667	7.3675	2.346590301	2.115168156	2.330063925	29.16805
20112377	34	4	74.77344285	16	0	5	19.05208333	5.083333333	8.0653125	0.468811151	4.234382641	3.597245457	61.01419896
10222853	34	4	85.77686516	20	1	5	8.229166667	4.5	6.38375	0.904338345	2.346972368	1.877644976	31.0343125
10248033	44	4	88.46817248	19	1	3	57.88541667	17.91666667	3.53875	2.076800539	0.440515543	0.397845896	2.31290625

apoe\_genotype = Apolipoprotein E genotype

cogdx = Final consensus cognitive diagnosis

educ = Years of education

msex 1=Male, 0=Female

braaksc = Braak stage

fixation\_interval (in hours)

PMI = Post-mortem interval (in hours)

Amyloid = Overall amyloid level - Mean of 8 brain regions

plaq\_d = Diffuse plaque burden (Diffuse plaque summary based on 5 regions)

plaq\_n = Neuritic plaque burden (Neuritic plaque summary based on 5 regions)

nft = Neurofibrillary tangle burden (Neurofibrillary tangle summary based on 5 regions)

tangles = Tangle density - Mean of 8 brain regions